EP4314035A1 - Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation - Google Patents

Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation

Info

Publication number
EP4314035A1
EP4314035A1 EP22713687.6A EP22713687A EP4314035A1 EP 4314035 A1 EP4314035 A1 EP 4314035A1 EP 22713687 A EP22713687 A EP 22713687A EP 4314035 A1 EP4314035 A1 EP 4314035A1
Authority
EP
European Patent Office
Prior art keywords
certain embodiments
long
acting
formula
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22713687.6A
Other languages
German (de)
English (en)
Inventor
Kennett Sprogøe
Mads Jens KJELGAARD-HANSEN
Nora Elisabeth ZOIS
Thomas TUXEN POULSEN
Yang YANG-MALTEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ascendis Pharma AS
Original Assignee
Ascendis Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma AS filed Critical Ascendis Pharma AS
Publication of EP4314035A1 publication Critical patent/EP4314035A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin

Definitions

  • the present invention relates to a long-acting growth hormone (GH) for use in the treatment of an inflammation-induced disease.
  • GH growth hormone
  • Non-alcoholic fatty liver disease is a disorder affecting as many as 1 in 3 - 5 adults and 1 in 10 children in the United States, and refers to conditions where there is accumulation of excess fat in the liver of people who drink little or no alcohol.
  • NASH non-alcoholic steatohepatitis
  • Some people with NAFLD may develop a more serious condition called non-alcoholic steatohepatitis (NASH): about 2 - 5% of adult Americans and up to 20% of those who are obese may suffer from NASH.
  • NASH non-alcoholic steatohepatitis
  • fat accumulation in the liver is associated with inflammation and different degrees of scarring/fibrosis.
  • NASH is a potentially serious condition that carries a substantial risk of progression to end-stage liver disease, cirrhosis and hepatocellular carcinoma.
  • Some patients who develop cirrhosis are at risk of liver failure and may eventually require a liver transplant.
  • the liver has an abundance of macrophages that upon activation accelerate the development of NASH by means of extensive inflammatory pathways.
  • the majority of macrophages present in liver tissue are the self-renewing, resident phagocytic Kupffer cells which may be split into Ml (proinflammatory) and M2 (immunoregulatory) phenotypes.
  • Ml and M2 function is well balanced to control inflammation.
  • NASH an imbalance towards Ml has been implicated in causing excess inflammation.
  • NAFLD/NASH Historically, a number of pharmacological interventions have been tried in NAFLD/NASH but with overall limited benefit. Antioxidant agents may arrest lipid peroxidation and cytoprotective agents may stabilize phospholipid membranes, but agents tried so far including ursodeoxycholic acid, vitamins E (a-tocopherol) and C, and pentoxifylline demonstrated no or only modest benefit. Most weight-loss studies in NAFLD/NASH have been pilot studies of short duration and limited success, reporting no or only a modest improvement in necroinflammation or fibrosis.
  • pioglitazone is also associated with a significantly increased risk of weight gain, edema, congestive heart failure, and osteoporotic fractures in both women and men.
  • Thyroid Hormone Receptor-b Thyroid Hormone Receptor-b (THR-b) agonist resmetirom
  • CCR2/CCR5 C-C Chemokine Receptor Type 2/5
  • SCD1 Stearoyl-CoA desaturase-1
  • SCD1 Stearoyl-CoA desaturase-1
  • SGLT-2 Selective Sodium Glucose Co Transporter-2
  • the Famesoid X Receptor (FXR) agonist obeticholic acid completed a Phase III trial for NASH by achieving one of the two FDA suggested primary endpoints: “>1 -stage improvement in liver fibrosis using the NASH Clinical Research Network (CRN) fibrosis score and no worsening of NASH” or “Resolution of NASH and no worsening of liver fibrosis using the NASH CRN fibrosis score”.
  • CRN NASH Clinical Research Network
  • results were not sufficient to obtain regulatory approval, indicating that the predicted benefit based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks for the treatment of patients with liver fibrosis due to NASH.
  • FGF Fibroblast Growth Factor
  • Pegbelfermin Fibroblast Growth Factor
  • Aldafermin Fibroblast Growth Factor Receptor l-b Klotho antibodies BFKB8488A and NGM313, the Glucagon Like Peptide 1 (GLP-1) receptor agonist Semaglutide, the dual receptor agonists with GLP-1 and Glucagon activity Cotadutide and Efinopegdutide, the dual receptor agonists with Gastric Inhibitory Polypeptide (GIP) and GLP-1 Tirzepatide, and the PPAR a/d/ agonist Lanifibranor.
  • GLP-1 Gastric Inhibitory Polypeptide
  • GLP-1 Tirzepatide the PPAR a/d/ agonist Lanifibranor.
  • the present invention relates to a long-acting growth hormone (GH) for use in the treatment of an inflammation-induced disease.
  • GH growth hormone
  • the inflammation-induced disease is an inflammation-induced disease of the liver.
  • the inflammation- induced disease is NAFED.
  • the inflammation-induced disease is NASH.
  • a stable level of growth hormone such as that obtained from administering a long-acting growth hormone to a patient, triggered the re-balancing of macrophage phenotypes between Ml and M2.
  • Such rebalancing of macrophage phenotypes is in certain embodiments achieved through an Ml reduction. In certain embodiments such rebalancing of macrophage phenotypes is achieved through an M2 induction.
  • Lise of a long-acting growth hormone reduces the administration frequency, which increases patients’ compliance and consequently may improve treatment outcomes.
  • growth hormone refers to all growth hormone protein sequences, preferably from mammalian species, more preferably from human and mammalian species, more preferably from human and murine species, and includes in certain embodiments also their variants, analogs, orthologs, homologs, and derivatives and fragments thereof. Growth hormone is characterized by promoting growth in the growing phase and maintains normal body composition, anabolism, and lipid metabolism.
  • human growth hormone or “hGH” refers to the hGH polypeptide of SEQ ID NO:l and includes its variants, homologs and derivatives exhibiting essentially the same biological activity, i.e. promoting growth in the growing phase and maintaining normal body composition, anabolism, and lipid metabolism.
  • hGH refers to the sequence of SEQ ID NO: 1.
  • SEQ ID NO:l has the following sequence:
  • GH variant refers to a GH protein from the same species that differs from a reference GFI protein, such as from the hGFI of SEQ ID NO:l.
  • GH variants are at least 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identical to a reference GH, such as the hGH of SEQ ID NO: 1.
  • a protein having an amino acid sequence at least, for example, 95% “identical” to a query amino acid sequence it is intended that the amino acid sequence of the subject protein is identical to the query sequence except that the subject protein sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence.
  • alterations of the reference sequence may occur at the amino (N-terminal) or carboxy terminal (C- terminal) positions of the reference amino acid sequence or anywhere between those terminal positions or in any combination thereof. These alterations of the reference sequence may either be interspersed among residues in the reference sequence or may be in one or more contiguous groups within the reference sequence.
  • Such GH variants may be naturally occurring variants, such as naturally occurring allelic variants encoded by one of several alternate forms of a GH occupying a given locus on a chromosome or an organism, or isoforms encoded by naturally occurring splice variants originating from a single primary transcript.
  • a GH variant may be a variant that is not known to occur naturally and that can be made mutagenesis techniques known in the art.
  • GH analog refers to GH of different and unrelated organisms which perform the same functions in each organism, but which did not originate from an ancestral structure that the organisms’ ancestors had in common. Instead, analogous GHs arose separately and then later evolved to perform the same or similar functions.
  • analogous GH proteins are proteins with quite different amino acid sequences but that perform the same biological activity, namely promoting growth in the growing phase and maintaining normal body composition, anabolism, and lipid metabolism.
  • GH ortholog refers to GH within two different species which sequences are related to each other via a common homologous GH in an ancestral species, but which have evolved to become different from each other.
  • GH homolog refers to GH of different organisms which perform the same functions in each organism, and which originate from an ancestral structure that the organisms’ ancestors had in common.
  • homologous GH proteins are proteins with quite similar amino acid sequences that perform the same biological activity, namely promoting growth in the growing phase and maintaining normal body composition, anabolism, and lipid metabolism.
  • such GH homologs may be defined as proteins exhibiting at least 40%, 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98% or 99% identity to a reference GH sequence, such as to the hGH of SEQ ID NO:l.
  • a GH according to the invention may be, for example: (i) one in which at least one of the amino acids residues is substituted with a conserved or non-conserved amino acid residue, in certain embodiments a conserved amino acid residue, and such substituted amino acid residue may or may not be one encoded by the genetic code; and/or (ii) one in which at least one of the amino acid residues includes a substituent group; and/or (iii) one in which the GH is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol); and/or (iv) one in which additional amino acids are fused to the hGH polypeptide, such as an IgG Fc fusion region peptide or leader or secretory sequence or a sequence which is employed for purification of the above form of the protein or a pre-protein sequence.
  • additional amino acids are fused to the hGH polypeptide, such as an IgG Fc fusion region peptide
  • the GH protein may be a monomer or multimer. Multimers may be dimers, trimers, tetramers or multimers comprising at least five monomeric polypeptide units. Multimers may also be homodimers or heterodimers. Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent association and/or may be indirectly linked, by for example, liposome formation.
  • the GH is a monomer, in particular an hGH monomer, such as an hGH monomer of SEQ ID NO:l.
  • GH fragment refers to any peptide or protein comprising a contiguous span of a part of the amino acid sequence of a GH protein, such as the hGH of SEQ ID NO: 1. More specifically, a GH fragment comprises at least 6, preferably at least 8 or 10, more preferably at least 12, 15, 20, 25, 30, 35, 40, 50, 60, 75, 100, 125, 150, 175, 191 consecutive amino acids of GH, such as the hGH of SEQ ID NO: 1.
  • the term “long-acting growth hormone” refers to a compound which comprises GH either in crystallized form or wherein the GH is embedded, fused or covalently conjugated to at least one other chemical compound or moiety, such as for example a polymer, fatty acid or fatty acid variant moiety, and has an increased clearance half-life in a patient’s body compared to unmodified GH, such as a clearance half-life that is at least 10-fold, at least 20-fold, at least 30-fold, at least 50- fold, at least 100-fold or at least 200-fold higher than the clearance half-life of the corresponding unmodified GH.
  • the GH is hGH, such as the hGH of SEQ ID NO: 1.
  • the term “clearance half-life” refers to the time until half of all molecules administered to a patient are cleared from the body.
  • the terms “reversible”, “reversibly”, “degradable” or “degradably” with regard to the attachment of a first moiety to a second moiety mean that the linkage that connects said first and second moiety is cleavable under physiological conditions, which are aqueous buffer at pH 7.4, 37°C, with a half-life ranging from one hour to three months, such as from 12 hours to two months, from one day to one month. Cleavage may be enzymatically or non-enzymatically and is in certain embodiments non-enzymatically.
  • stable or “permanent” with regard to the attachment of a first moiety to a second moiety means that the linkage that connects said first and second moiety is cleavable with a half-life of more than three months under physiological conditions.
  • reagent means a chemical compound, which comprises at least one functional group for reaction with the functional group of another chemical compound or drug. It is understood that a drug comprising a functional group (such as a primary or secondary amine or hydroxyl functional group) is also a reagent.
  • moiety means a part of a molecule, which lacks one or more atom(s) compared to the corresponding reagent. If, for example, a reagent of the formula “H-X-H” reacts with another reagent and becomes part of the reaction product, the corresponding moiety of the reaction product has the structure “H-X-” or “-X-”, whereas each indicates attachment to another moiety. Accordingly, a drug moiety is released from a reversible linkage as a drug.
  • sequence or chemical structure of a group of atoms is provided which group of atoms is attached to two moieties or is interrupting a moiety, said sequence or chemical structure can be attached to the two moieties in either orientation, unless explicitly stated otherwise.
  • a moiety “-C(O)N(R 1 )-” can be attached to two moieties or interrupting a moiety either as Similarly, a moiety can be attached to two moieties or can interrupt a moiety either as or as
  • substituted means that one or more -H atoms of a molecule or moiety are replaced by a different atom or a group of atoms, which are referred to as “substituent”.
  • substituted refers in certain embodiments to a moiety selected from the group consisting of halogen, -CN, -COOR xl , -OR xl , -C(O)R xl , -C(O)N(R xl R xla ), -S(O) 2 N(R xl R xla ), -S(O)N(R xl R xla ), -S(O) 2 R x1 , -S(O)R x1 , -N(R xl )S(O) 2 N(R xla R xlb ), -SR xl , -N(R xl R xla ), -N0 2 , -0C(O)R xl , -N(R xl )C(O)R xla , -N(R xl )S(O) 2 R
  • -R xl , -R xla , -R xlb are independently of each other selected from the group consisting of -H, -T°, C 1-50 alkyl, C2-50 alkenyl, and C 2 -5o alkynyl; wherein -T°, C 1-50 alkyl, C2-50 alkenyl, and C 2 -so alkynyl are optionally substituted with one or more -R x2 , which are the same or different and wherein C 1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T 0 -, -C(O)0-, -0-, -C(O)-,
  • each -R x3 , -R x3a , -R x4 , -R x4a , -R x4b is independently selected from the group consisting of -H and Ci- 6 alkyl; wherein Ci- 6 alkyl is optionally substituted with one or more halogen, which are the same or different.
  • a maximum of 6 -H atoms of an optionally substituted molecule are independently replaced by a substituent, e.g. 5 -H atoms are independently replaced by a substituent, 4 -H atoms are independently replaced by a substituent, 3 -H atoms are independently replaced by a substituent, 2 -H atoms are independently replaced by a substituent, or 1 -H atom is replaced by a substituent.
  • fatty acid refers to a saturated or unsaturated monocarboxylic acid having an aliphatic tail, which may include from 4 to 28 carbon atoms.
  • the fatty acid may be saturated or unsaturated, linear or branched.
  • fatty acid variant refers to a modified fatty acid in which certain carbon atoms may be replaced by other atoms or groups of atoms and which may be substituted.
  • peptide refers to a chain of at least 2 and up to and including 50 amino acid monomer moieties linked by peptide (amide) linkages.
  • peptide also includes peptidomimetics, such as D-peptides, peptoids or beta-peptides, and covers such peptidomimetic chains with up to and including 50 monomer moieties. Also included are cyclic peptides, such as lasso peptides.
  • protein refers to a chain of more than 50 amino acid monomer moieties, which may also be referred to as “amino acid residues”, linked by peptide linkages, in which in certain embodiments no more than 12000 amino acid monomers are linked by peptide linkages, such as no more than 10000 amino acid monomer moieties, no more than 8000 amino acid monomer moieties, no more than 5000 amino acid monomer moieties or no more than 2000 amino acid monomer moieties.
  • the term “about” in combination with a numerical value is used to indicate a range ranging from and including the numerical value plus and minus no more than 25% of said numerical value, in certain embodiments plus and minus no more than 20% of said numerical value and in certain embodiments plus and minus no more than 10% of said numerical value.
  • the phrase “about 200” is used to mean a range ranging from and including 200 +/- 25%, i.e. ranging from and including 150 to 250; in certain embodiments 200 +/- 20%, i.e. ranging from and including 160 to 240; and in certain embodiments from and including 200 +/- 10%, i.e. ranging from and including 180 to 220.
  • polymer means a molecule comprising repeating structural units, i.e. the monomers, connected by chemical bonds in a linear, circular, branched, crosslinked or dendrimeric way or a combination thereof, which may be of synthetic or biological origin or a combination of both. It is understood that a polymer may also comprise one or more other chemical groups and/or moieties, such as, for example, one or more functional groups. Likewise, it is understood that also a peptide or protein is a polymer, even though the side chains of individual amino acid residues may be different. In certain embodiments a soluble polymer has a molecular weight of at least 0.5 kDa, e.g.
  • the polymer in certain embodiments has a molecular weight of at most 1000 kDa, such as at most 750 kDa, such as at most 500 kDa, such as at most 300 kDa, such as at most 200 kDa, such as at most 100 kDa. It is understood that for insoluble polymers, such as hydrogels, no meaningful molecular weight ranges can be provided.
  • polymeric means a reagent or a moiety comprising one or more polymer(s) or polymer moiety/moieties.
  • a polymeric reagent or moiety may optionally also comprise one or more other moiety/moieties, which are in certain embodiments selected from the group consisting of:
  • linkages selected from the group comprising wherein dashed lines indicate attachment to the remainder of the moiety or reagent, and -R and -R a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl and 3,3-dimethylpropyl.
  • the molecular weight ranges, molecular weights, ranges of numbers of monomers in a polymer and numbers of monomers in a polymer as used herein refer to the number average molecular weight and number average of monomers, i.e. to the arithmetic mean of the molecular weight of the polymer or polymeric moiety and the arithmetic mean of the number of monomers of the polymer or polymeric moiety.
  • any integer given for “x” therefore corresponds to the arithmetic mean number of monomers.
  • Any range of integers given for “x” provides the range of integers in which the arithmetic mean numbers of monomers lie.
  • An integer for “x” given as “about x” means that the arithmetic mean numbers of monomers lie in a range of integers of x +/- 25%, preferably x+/- 20% and more preferably x +/- 10%.
  • number average molecular weight means the ordinary arithmetic mean of the molecular weights of the individual polymers.
  • PEG-based in relation to a moiety or reagent means that said moiety or reagent comprises PEG.
  • a PEG-based moiety or reagent comprises at least 10% (w/w) PEG, such as at least 20% (w/w) PEG, such as at least 30% (w/w) PEG, such as at least 40% (w/w) PEG, such as at least 50% (w/w), such as at least 60 (w/w) PEG, such as at least 70% (w/w) PEG, such as at least 80% (w/w) PEG, such as at least 90% (w/w) PEG, such as at least 95%.
  • the remaining weight percentage of the PEG-based moiety or reagent are other moieties that in certain embodiments are selected from the following moieties and linkages:
  • linkages selected from the group comprising wherein dashed lines indicate attachment to the remainder of the moiety or reagent, and -R and -R a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl and 3,3-dimethylpropyl.
  • hyaluronic acid-based is used accordingly.
  • PEG-based comprising at least X% PEG in relation to a moiety or reagent means that said moiety or reagent comprises at least X% (w/w) ethylene glycol units (-CH2CH2O-), wherein the ethylene glycol units may be arranged blockwise, alternating or may be randomly distributed within the moiety or reagent and in certain embodiments all ethylene glycol units of said moiety or reagent are present in one block; the remaining weight percentage of the PEG-based moiety or reagent are other moieties that in certain embodiments are selected from the following moieties and linkages:
  • Ci- 50 alkyl C 2-50 alkenyl, C 2-50 alkynyl, C3- 10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, phenyl, naphthyl, indenyl, indanyl, and tetralinyl; and
  • linkages selected from the group comprising wherein dashed lines indicate attachment to the remainder of the moiety or reagent, and -R and -R a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3- dimethylbutyl and 3,3-dimethylpropyl.
  • the term “hyaluronic acid-based comprising at least X% hyaluronic acid” is used accordingly.
  • hydrogel means a hydrophilic or amphiphilic polymeric network composed of homopolymers or copolymers, which is insoluble due to the presence of hydrophobic interactions, hydrogen bonds, ionic interactions, covalent chemical crosslinks or any combination thereof.
  • a hydrogel is insoluble due to the presence of covalent chemical crosslinks.
  • the crosslinks provide the network structure and physical integrity.
  • interrupted means that a moiety is inserted between two carbon atoms or - if the insertion is at one of the moiety’s ends - between a carbon or heteroatom and a hydrogen atom.
  • CM alkyl alone or in combination means a straight-chain or branched alkyl moiety having 1 to 4 carbon atoms. If present at the end of a molecule, examples of straight- chain or branched CM alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. When two moieties of a molecule are linked by the CM alkyl, then examples for such CM alkyl groups are -CH2-, -CH2-CH2-,
  • CM alkyl carbon may optionally be replaced by a substituent as defined above.
  • a CM alkyl may be interrupted by one or more moieties as defined below.
  • C M alkyl alone or in combination means a straight-chain or branched alkyl moiety having 1 to 6 carbon atoms. If present at the end of a molecule, examples of straight- chain and branched CM alkyl groups are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec- butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3- methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl.
  • CM alkyl groups When two moieties of a molecule are linked by the CM alkyl group, then examples for such CM alkyl groups are -CH2-, -CH2-CH2-, -CH(CH 3 )-, -CH2-CH2-CH2-, -CH(C 2 H 5 )- and -C(CH 3 ) 2 -.
  • Each hydrogen atom of a CM carbon may optionally be replaced by a substituent as defined above.
  • a CM alkyl may be interrupted by one or more moieties as defined below.
  • C MO alkyl means an alkyl chain having 1 to 10, 1 to 20 or 1 to 50 carbon atoms, respectively, wherein each hydrogen atom of the Cmo, C 1 - 2o or C 1-50 carbon may optionally be replaced by a substituent as defined above.
  • a C MO or C 1-50 alkyl may be interrupted by one or more moieties as defined below.
  • C 2-10 alkenyl means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon double bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms.
  • Each hydrogen atom of a C 2-10 alkenyl, C 2-20 alkenyl or C 2-50 alkenyl group may optionally be replaced by a substituent as defined above.
  • a C 2-10 alkenyl, C 2-20 alkenyl or C 2-50 alkenyl may be interrupted by one or more moieties as defined below.
  • C 2-6 alkynyl alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon-carbon triple bond having 2 to 6 carbon atoms. If present at the end of a molecule, examples are -CoCH, -CH 2 -CoCH, -CH 2 -CH 2 -CoCH and CEb-CoC-CEl 3 . When two moieties of a molecule are linked by the alkynyl group, then an example is -CoC-. Each hydrogen atom of a C 2-6 alkynyl group may optionally be replaced by a substituent as defined above. Optionally, one or more double bond(s) may occur. Optionally, a C 2-6 alkynyl may be interrupted by one or more moieties as defined below.
  • C 2-10 alkynyl C 2-20 alkynyl
  • C 2-50 alkynyl alone or in combination means a straight-chain or branched hydrocarbon moiety comprising at least one carbon- carbon triple bond having 2 to 10, 2 to 20 or 2 to 50 carbon atoms, respectively.
  • Each hydrogen atom of a C 2-10 alkynyl, C 2-20 alkynyl or C 2-50 alkynyl group may optionally be replaced by a substituent as defined above.
  • one or more double bond(s) may occur.
  • a C2-10 alkynyl, C 2-2o alkynyl or C2-50 alkynyl may be interrupted by one or more moieties as defined below.
  • a C alkyl, CM alkyl, Ci-io alkyl, C 1 - 2o alkyl, C 1-50 alkyl, C2-6 alkenyl, C2-10 alkenyl, C 2-2o alkenyl, C2-50 alkenyl, C2-6 alkynyl, C2-10 alkynyl, C 2-2o alkenyl or C2-50 alkynyl may optionally be interrupted by one or more moieties which are preferably selected from the group consisting of wherein dashed lines indicate attachment to the remainder of the moiety or reagent; and
  • -R and -R a are independently of each other selected from the group consisting of -H, and methyl, ethyl, propyl, butyl, pentyl and hexyl.
  • C3-10 cycloalkyl means a cyclic alkyl chain having 3 to 10 carbon atoms, which may be saturated or unsaturated, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclononyl or cyclodecyl.
  • Each hydrogen atom of a C3-10 cycloalkyl carbon maybe replaced by a substituent as defined above.
  • the term "C3-10 cycloalkyl” also includes bridged bicycles like norbomane or norbomene.
  • 8- to 30-membered carbopolycyclyl or “8- to 30-membered carbopolycycle” means a cyclic moiety of two or more rings with 8 to 30 ring atoms, where two neighboring rings share at least one ring atom and that may contain up to the maximum number of double bonds (aromatic or non-aromatic ring which is fully, partially or un-saturated).
  • an 8- to 30-membered carbopolycyclyl means a cyclic moiety of two, three, four or five rings, more preferably of two, three or four rings.
  • 3- to 10-membered heterocycles include but are not limited to aziridine, oxirane, thiirane, azirine, oxirene, thiirene, azetidine, oxetane, thietane, furan, thiophene, pyrrole, pyrroline, imidazole, imidazoline, pyrazole, pyrazoline, oxazole, oxazoline, isoxazole, isoxazoline, thiazole, thiazoline, isothiazole, isothiazoline, thiadiazole, thiadiazoline, tetrahydrofuran, tetrahydrothiophene, pyrrolidine, imidazolidine, pyrazolidine, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, sulfolane, pyran, dihydropyran, tetra
  • Examples for an 8- to 11-membered heterobicycle are indole, indoline, benzofuran, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzimidazole, benzimidazoline, quinoline, quinazoline, dihydroquinazoline, quinoline, dihydroquinoline, tetrahydroquinoline, decahydroquinoline, isoquinoline, decahydroisoquinoline, tetrahydroisoquinoline, dihydroisoquinoline, benzazepine, purine and pteridine.
  • 8- to 11- membered heterobicycle also includes spiro structures of two rings like l,4-dioxa-8- azaspiro[4.5]decane or bridged heterocycles like 8-aza-bicyclo[3.2.1]octane.
  • Each hydrogen atom of an 8- to 11-membered heterobicyclyl or 8- to 11-membered heterobicycle carbon may be replaced by a substituent as defined below.
  • the phrase “the pair R7R y is joined together with the atom to which they are attached to form a C3-10 cycloalkyl or a 3- to 10-membered heterocyclyl” in relation with a moiety of the structure means that R x and R y form the following structure: wherein R is C3-10 cycloalkyl or 3- to 10-membered heterocyclyl.
  • halogen means fluoro, chloro, bromo or iodo. It is generally preferred that halogen is fluoro or chloro.
  • the term “functional group” means a group of atoms which can react with other groups of atoms.
  • the invention also comprises its corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts.
  • the long-acting GH comprising acidic groups may be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or as ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids.
  • Long-acting GH comprising one or more basic groups i.e.
  • acids which can be protonated, can be present and can be used according to the invention in the form of their addition salts with inorganic or organic acids.
  • suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art.
  • the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions).
  • inner salts or betaines zwitterions
  • the respective salts can be obtained by customary methods, which are known to the person skilled in the art like, for example by contacting these compounds with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts.
  • the present invention also includes all salts of the long- acting GH which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
  • pharmaceutically acceptable means a substance that does not cause harm when administered to a patient and preferably means approved by a regulatory agency, such as the EMA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, such as for use in humans.
  • a regulatory agency such as the EMA (Europe) and/or the FDA (US) and/or any other national regulatory agency for use in animals, such as for use in humans.
  • excipient refers to a diluent, adjuvant, or vehicle with which the therapeutic, such as a drug or prodrug, is administered.
  • Such pharmaceutical excipient can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, including but not limited to peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred excipient when the pharmaceutical composition is administered orally.
  • Saline and aqueous dextrose are preferred excipients when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions are preferably employed as liquid excipients for injectable solutions.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, mannitol, trehalose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • the pharmaceutical composition can also contain minor amounts of wetting or emulsifying agents, pH buffering agents, like, for example, acetate, succinate, tris, carbonate, phosphate, HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), MES (2- (A-morpholino)cthancsul tonic acid), or can contain detergents, like Tween, poloxamers, poloxamines, CHAPS, Igepal, or amino acids like, for example, glycine, lysine, or histidine.
  • pH buffering agents like, for example, acetate, succinate, tris, carbonate, phosphate, HEPES (4-(2-hydroxyethyl)-l-piperazineethanesulfonic acid), MES (2- (A-morpholino)cthancsul tonic acid
  • detergents like Tween, poloxamers, poloxamines, CHAPS, Igepal, or amino acids like, for example,
  • the pharmaceutical composition can be formulated as a suppository, with traditional binders and excipients such as triglycerides.
  • Oral formulation can include standard excipients such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc.
  • Such compositions will contain a therapeutically effective amount of the drug or biologically active moiety, together with a suitable amount of excipient so as to provide the form for proper administration to the patient.
  • the formulation should suit the mode of administration.
  • the long-acting growth hormone inhibits recruitment of inflammatory monocytes to the site of inflammation.
  • site of inflammation is the liver, if the inflammation- induced disease is NAFLD, in particular NASH.
  • administration of the long- acting growth hormone leads to an increase in HLA-G in the liver, if the inflammation-induced disease is NAFLD, in particular NASH.
  • administration of the long-acting growth hormone results in an increase in IGF-1 levels. It is understood that in case animal studies are performed that the corresponding genes from such animal species are used, for example the murine ortholog of HLA-G is H2/B1.
  • administration of the long-acting growth hormone leads to a change in one or more markers of hepatic inflammation selected from the group consisting of cytokines, chemokines and other transcriptional and histological markers.
  • the long-acting growth hormone for use in the treatment of an inflammation-induced disease, such as NAFLD and in particular NASH leads to an improvement of transcriptional or histological markers of fibrosis.
  • administration of the long-acting growth hormone leads to a reduction in steatosis.
  • the long-acting growth hormone leads to a regeneration of the liver if the inflammation-induced disease is an inflammation-induced disease of the liver.
  • the long-acting growth hormone is administered to the patient once a week. In certain embodiments the long-acting growth hormone is administered to the patient once every two weeks. In certain embodiments the long-acting growth hormone is administered to the patient once every four weeks. In certain embodiments the long-acting growth hormone is administered to the patient once a month.
  • the present invention relates to a long-acting GH for use in the treatment of an inflammation-induced disease, wherein the treatment comprises the steps of (a) administering at least a first dose of the long-acting GH to a patient having an inflammation- induced disease;
  • IGF-1 Insulin-like Growth Factor-1
  • step (c) no dose adjustments are required in step (c) if the IGF-1 levels fall into a standard deviation score ranging from 0 to +3.
  • steps (a) to (c) are repeated until IGF- 1 levels are stable in a range from 0 to +3 standard deviation scores.
  • the dose of the long-acting GH is reduced in step (c) by at least 5% if IGF-1 levels are above a standard deviation score of +2 and increased by at least 5% if IGF-1 levels are below a standard deviation score of +0.5. Accordingly, in such embodiments no dose adjustments are required in step (c) if the IGF-1 levels fall into a standard deviation score ranging from +0.5 to +2. In certain embodiments steps (a) to (c) are repeated until IGF-1 levels are stable in a range from +0.5 to +2 standard deviation scores.
  • Embodiments for the inflammation-induced disease, administration frequencies and the long-acting growth hormone are as described elsewhere herein.
  • a dose reduction in step (c) is by 5%. In certain embodiments a dose reduction in step (c) is by 6%. In certain embodiments a dose reduction in step (c) is by 7%. In certain embodiments a dose reduction in step (c) is by 8%. In certain embodiments a dose reduction in step (c) is by 9%. In certain embodiments a dose reduction in step (c) is by 10%. In certain embodiments a dose reduction in step (c) is by 11%. In certain embodiments a dose reduction in step (c) is by 12%. In certain embodiments a dose reduction in step (c) is by 13%. In certain embodiments a dose reduction in step (c) is by 14%.
  • a dose reduction in step (c) is by 15%. In certain embodiments a dose reduction in step (c) is by 16%. In certain embodiments a dose reduction in step (c) is by 17%. In certain embodiments a dose reduction in step (c) is by 18%. In certain embodiments a dose reduction in step (c) is by 19%. In certain embodiments a dose reduction in step (c) is by 20%. In certain embodiments a dose increase in step (c) is by 5%. In certain embodiments a dose increase in step (c) is by 6%. In certain embodiments a dose increase in step (c) is by 7%. In certain embodiments a dose increase in step (c) is by 8%.
  • a dose increase in step (c) is by 9%. In certain embodiments a dose increase in step (c) is by 10%. In certain embodiments a dose increase in step (c) is by 11%. In certain embodiments a dose increase in step (c) is by 12%. In certain embodiments a dose increase in step (c) is by 13%. In certain embodiments a dose increase in step (c) is by 14%. In certain embodiments a dose increase in step (c) is by 15%. In certain embodiments a dose increase in step (c) is by 16%. In certain embodiments a dose increase in step (c) is by 17%. In certain embodiments a dose increase in step (c) is by 18%. In certain embodiments a dose increase in step (c) is by 19%. In certain embodiments a dose increase in step (c) is by 20%.
  • the present invention relates to a long-acting GH for use in the treatment of an inflammation-induced disease, wherein the treatment comprises the steps of
  • Embodiments for the inflammation-induced disease, administration frequencies and the long-acting growth hormone are as described elsewhere herein.
  • biomarkers indicative of Ml and M2 macrophages are measured prior to initiation of the treatment with the long-acting GH.
  • the biomarkers indicative of Ml macrophages are selected from the group consisting of interleukin (IL)- 1 b, IL-6, IL-12, IL-23, IL-27, tumor necrosis factor a (TNF-a), interferon g (IFN-y), monocyte chemoattractant protein (MCP)-l, CCL2, CCL3, CCL5, CXCL8, CXCL9, CXCL10, CXCL1, CXCL16, CCR2, CCR7, IL1R1, TLR2, TLR4, MARCO, CD1 lc, CD38 and iNOS.
  • IL interleukin
  • TNF-a tumor necrosis factor a
  • IFN-y interferon g
  • MCP monocyte chemoattractant protein
  • the biomarkers indicative of Ml macrophages are selected from the group consisting of IL-6, TNF-a, CD1 lc and iNOS.
  • the biomarkers indicative of M2 macrophages are selected from the group consisting of IL-2, IL-4, IL-10, IL-13, CCL17, CCL18, CCL22, CCL24, CCL13, CCL16, CXCR1, CXCR2, CD14, CD23, CD36, CD163, mannose receptor (CD206), scavenger receptor A, Chi313/Yml, Retnla/Fizz-1 and arginase-1.
  • the biomarkers indicative of M2 macrophages are selected from the group consisting of IL-10, CD36, CD206, Retnla/Fizz-1 and arginase-1.
  • the dose of the long-acting growth hormone is increased, if the Ml to M2 macrophage ratio is unbalanced, such as when the biomarkers indicative of Ml type of macrophage are still increasing or dominant compared to biomarkers indicative of M2 macrophage.
  • such dose increase is an increase of 5%.
  • such dose increase is an increase of 6%.
  • such dose increase is an increase of 7%.
  • such dose increase is an increase of 8%.
  • such dose increase is an increase of 9%.
  • such dose increase is an increase of 10%.
  • such dose increase is an increase of 11%.
  • such dose increase is an increase of 12%.
  • such dose increase is an increase of 13%. In certain embodiments such dose increase is an increase of 14%. In certain embodiments such dose increase is an increase of 15%. In certain embodiments such dose increase is an increase of 16%. In certain embodiments such dose increase is an increase of 17%. In certain embodiments such dose increase is an increase of 18%. In certain embodiments such dose increase is an increase of 19%. In certain embodiments such dose increase is an increase of 20%. If in step (c) the Ml to M2 macrophage ratio is balanced, such as when the biomarkers indicative of Ml and M2 are reaching a steady state, the dose is in certain embodiments not adjusted, but stays constant.
  • dose adjustments in step (c) are accompanied by measuring IGF-1 levels and adjustments of the dose of the long-acting GH are such that IGF-1 levels are in a range from 0 to +3 standard deviation scores. In certain embodiments dose adjustments in step (c) are accompanied by measuring IGF-1 levels and adjustments of the dose of the long-acting GFI are such that IGF-1 levels are in a range from +0.5 to +2 standard deviation scores.
  • steps (b) and (c) are repeated until macrophage rebalancing is achieved.
  • the present invention relates to a method of treating an inflammation-induced disease, wherein the method comprises the step of administering a pharmaceutically effective amount of a long-acting growth hormone.
  • the long-acting growth hormone and the inflammation-induced disease are described elsewhere herein.
  • the present invention relates to a method comprising the steps of
  • IGF-1 Insulin-like Growth Factor-1
  • step (c) no dose adjustments are required in step (c) if the IGF-1 levels fall into a standard deviation score ranging from 0 to +3.
  • steps (a) to (c) are repeated until IGF- 1 levels are stable in a range from 0 to +3 standard deviation scores.
  • the dose of the long-acting GH is reduced in step (c) by at least 5% if IGF-1 levels are above a standard deviation score of +2 and increased by at least 5% if IGF-1 levels are below a standard deviation score of +0.5. Accordingly, in such embodiments no dose adjustments are required in step (c) if the IGF-1 levels fall into a standard deviation score ranging from +0.5 to +2. In certain embodiments steps (a) to (c) are repeated until IGF-1 levels are stable in a range from +0.5 to +2 standard deviation scores.
  • Embodiments for the dose adjustments of step (c) are as described elsewhere herein.
  • the present invention relates to a method comprising the steps of
  • steps (b) and (c) are repeated until macrophage rebalancing is achieved.
  • the long-acting growth hormone comprises at least one human growth hormone (hGH).
  • the hGH has the sequence of SEQ ID NO:l.
  • the hGH has a sequence with at least 90% identity to the sequence of SEQ ID NO: 1.
  • the hGH has a sequence with at least 92% identity to the sequence of SEQ ID NO:l.
  • the hGH has a sequence with at least 94% identity to the sequence of SEQ ID NO:l.
  • the hGH has a sequence with at least 95% identity to the sequence of SEQ ID NO: 1.
  • the hGH has a sequence with at least 96% identity to the sequence of SEQ ID NO:l.
  • the hGH has a sequence with at least 97% identity to the sequence of SEQ ID NO:l. In certain embodiments the hGH has a sequence with at least 98% identity to the sequence of SEQ ID NO: 1. In certain embodiments the hGH has a sequence with at least 99% identity to the sequence of SEQ ID NO: 1.
  • the long-acting GH comprises growth hormone non-covalently embedded or encapsulated in a polymer or lipid-comprising matrix. In certain embodiments the long-acting GH comprises growth hormone non-covalently embedded or encapsulated in a polymer.
  • a preferred polymer matrix comprises a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly( acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylmethacrylamides), poly(hydroxy
  • the polymer is selected from the group consisting of PEG, polylactid-co- glycolid (PLGA) and hyaluronic acid.
  • the polymer is PEG.
  • the polymer is PLGA.
  • the polymer is hyaluronic acid.
  • the polymer matrix is a hydrogel comprising a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly( ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines), poly(hydroxymethacrylates), poly(hydroxypropylme
  • the hydrogel comprises a polymer selected from the group consisting of PEG, polylactid-co-glycolid (PLGA) and hyaluronic acid.
  • the hydrogel is a PEG-based hydrogel.
  • the hydrogel comprises PLGA.
  • the hydrogel comprises hyaluronic acid.
  • the long-acting growth hormone is crystalline growth hormone.
  • the long-acting growth hormone comprises a growth hormone moiety fused to at least one natural or unnatural amino acid sequence. It is understood that such amino acid sequence comprises one or more amino acid residues.
  • such growth hormone fusion protein comprises a recognition sequence for enzymatic cleavage between a growth hormone moiety and a natural or unnatural amino acid sequence.
  • the growth hormone fusion protein comprises a chemical cleavage site between a growth hormone moiety and a natural or unnatural amino acid sequence.
  • the amino acid sequence is selected from the group consisting of carboxyl-terminal peptide of the chorionic gonadotropin as described in US 2012/0035101; albumin; XTEN sequences as described in WO2011123813A2; proline/alanine random coil sequences as described in WO2011/144756A1; proline/alanine/serine random coil sequences as described in WO2008/155134; and Fc fusion proteins.
  • the long- acting growth hormone comprises a hGH-CTP fusion protein.
  • the long-acting growth hormone comprises a hGH-XTEN fusion protein.
  • the long-acting growth hormone comprises a hGH-HSA fusion protein.
  • the long-acting growth hormone comprises a hGH-Fc fusion protein.
  • the long-acting growth hormone comprises a growth hormone moiety covalently conjugated to one or more chemical moiety.
  • the chemical moiety is a polymeric moiety, such as a polymeric moiety that comprises a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly( cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly( ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(gly
  • the polymeric moiety comprises a linear, branched, dendrimeric or cyclic polymer or any combination thereof.
  • the polymeric moiety comprises a linear polymer.
  • the polymeric moiety comprises a branched polymer, such as a polymer with one, two, three, four or five branching points, which branching points may in certain embodiments be selected from the group consisting of -N ⁇ , -CR bl ⁇ and >C ⁇ , wherein -R bl is selected from the group consisting of -H, Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl; wherein Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally substituted with one or more -R b2 , which are the same or different, and wherein Ci- 6 alkyl, C2-6 alkenyl and C2-6 alkynyl are optionally interrupted with -C(O)0-, -
  • the polymeric moiety comprises a dendrimeric polymer. In certain embodiments the polymeric moiety comprises a cyclic polymer.
  • the chemical moiety is a fatty acid or fatty acid variant moiety, which may optionally be substituted. In certain embodiments such fatty acid or fatty acid variant moiety has a structure as disclosed in W02005/027978A2 and W02014/060512A1.
  • the long-acting growth hormone is a growth hormone-fatty acid conjugate. In certain embodiments the long-acting growth hormone is a growth hormone-fatty acid variant conjugate.
  • the long-acting growth hormone comprises a moiety of formula (F):
  • the dashed line in formula (F) indicates attachment to a growth hormone moiety.
  • the dashed line in formula (F) indicates attachment to the sulfur of a thiol of a cysteine side chain of a growth hormone moiety.
  • the growth hormone moiety is of SEQ ID NO:l, in which the leucine at position 101 is mutated to cysteine and wherein the dashed line of formula (F) indicates attachment to this cysteine at position 101. It is understood that “attachment to this cysteine” means attachment to the sulfur of the thiol of the cysteine.
  • the fatty acid or fatty acid variant moiety has the structure of formula (F-i):
  • the dashed line in formula (F-i) indicates attachment to a growth hormone moiety. In certain embodiments the dashed line in formula (F-i) indicates attachment to the sulfur of a thiol of a cysteine side chain of a growth hormone moiety. In certain embodiments the growth hormone moiety is of SEQ ID NO:l, in which the leucine at position 101 is mutated to cysteine and wherein the dashed line of formula (F-i) indicates attachment to this cysteine at position 101. It is understood that “attachment to this cysteine” means attachment to the sulfur of the thiol of the cysteine.
  • the long-acting GH is of formula (F-i), with the growth hormone moiety having the sequence of SEQ ID NO:l, in which the leucine at position 101 is replaced by a cysteine and to which cysteine the dashed line indicates attachment via the sulfur of its thiol, the long-acting GH is somapacitan, which is marketed as Sogroya ® .
  • the bond between the growth hormone moiety and the chemical moiety is a stable covalent bond. In certain embodiments the bond between the growth hormone moiety and the chemical moiety is a reversible covalent bond. If the growth hormone moiety is reversibly conjugated to one or more chemical moiety such conjugate may also be referred to as prodrug.
  • the long-acting growth hormone is a growth hormone conjugate or a pharmaceutically acceptable salt thereof of formula (la) or (lb) wherein each -D is independently a growth hormone moiety; each -L 1 - is independently a linker moiety covalently and reversibly attached to -D; each -L 2 - is independently a chemical bond or is a spacer moiety; each -Z is independently a polymeric moiety or a fatty acid moiety, which is optionally substituted; x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 and 16; and y is an integer selected from the group consisting of 2, 3, 4 and 5.
  • the growth hormone conjugate is of formula (la). In certain embodiments x is 1. In certain embodiments the growth hormone conjugate is of formula (lb). In certain embodiments y is 2. In certain embodiments y is 3. In certain embodiments y is 4. In certain embodiments all moieties -D of the conjugate are identical. In certain embodiments the conjugate of the present invention comprises more than one type of -D, such as two, three, four or five different types of moiety -D, provided there is more than one moiety -D present in the conjugate.
  • -D of formula (la) and (lb) has the sequence of SEQ ID NO:l. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 90% identity to the sequence of SEQ ID NO:l. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 92% identity to the sequence of SEQ ID NO:l. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 94% identity to the sequence of SEQ ID NO:l. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 95% identity to the sequence of SEQ ID NO:l.
  • -D of formula (la) and (lb) has a sequence with at least 96% identity to the sequence of SEQ ID NO:l. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 97% identity to the sequence of SEQ ID NO: 1. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 98% identity to the sequence of SEQ ID NO:l. In certain embodiments -D of formula (la) and (lb) has a sequence with at least 99% identity to the sequence of SEQ ID NO: 1.
  • all moieties -L 1 - of the conjugate are identical, provided there is more than one moiety -L 1 - present in the conjugate.
  • the conjugate of the present invention comprises more than one type of -L 1 -, such as two, three, four or five different moieties -L 1 -.
  • the moiety -L 1 - may be any moiety that allows for the reversible attachment of -D.
  • -L 1 - is a traceless linker, i.e. a linker from the drug D-H is released in its unmodified form, which may also be referred to as free form.
  • the moiety -L 1 - may be attached to a proteinogenic or non-proteinogenic amino acid residue of -D. In certain embodiments -L 1 - is attached to a non-proteinogenic amino acid residue. In certain embodiments attachment of -L 1 - is to a proteinogenic amino acid residue. If attachment occurs at a proteinogenic amino acid residue, said proteinogenic amino acid residue is in certain embodiments selected from the group consisting of cysteine, methionine, histidine, lysine, tryptophan, serine, threonine, tyrosine, aspartic acid, glutamic acid, glutamine and arginine.
  • such proteinogenic amino acid residue is selected from the group consisting of cysteine, histidine, lysine, tryptophan, serine, threonine, tyrosine, aspartic acid, glutamic acid and arginine.
  • cysteine is cysteine.
  • proteinogenic amino acid is histidine.
  • proteinogenic amino acid is lysine.
  • proteinogenic amino acid is tryptophan.
  • proteinogenic amino acid is serine.
  • such proteinogenic amino acid is threonine.
  • such proteinogenic amino acid is aspartic acid.
  • such proteinogenic amino acid is glutamic acid.
  • such proteinogenic amino acid is arginine.
  • the moiety -L 1 - may be connected to -D through any type of linkage, provided that it is reversible, and it is understood that the functional group of -D chosen for attachment influences the linkage between -L 1 - and -D.
  • -L 1 - is connected to -D through a linkage selected from the group consisting of amide, ester, carbamate, acetal, aminal, imine, oxime, hydrazone, disulfide and acyl guanidine.
  • -L 1 - is connected to -D through a linkage selected from the group consisting of amide, ester, carbamate and acylguanidine.
  • linkages may not be reversible per se, but that reversibility may be an effect of certain groups of atoms or moieties present in -L 1 -.
  • -L 1 - is connected to -D through an ester linkage.
  • -L 1 - is connected to -D through a carbamate linkage.
  • -L 1 - is connected to -D through an acylguanidine.
  • -L 1 - is connected to -D through an amide linkage.
  • -D is conjugated to -L 1 - through the nitrogen of an amine functional group of -D.
  • Such amine functional group may be the N-terminal amine functional group of -D or may be the amine functional group from the side chain of a lysine residue.
  • -D is conjugated to -L 1 - via the nitrogen of the N-terminal amine functional group.
  • -D is conjugated to -L 1 - through the nitrogen of an amine functional group from the side chain of a lysine residue.
  • -L 1 - is connected to -D via the nitrogen of an amine functional group of a side chain of a lysine residue of -D and the linkage formed between -D and -L 1 - is a carbamate.
  • -L 1 - is connected to -D via the nitrogen of an amine functional group of a side chain of a lysine residue of -D and the linkage formed between -D and -L 1 - is an amide.
  • -L 1 - has a structure as disclosed in WO 2009/095479 A2.
  • the moiety -L 1 - is of formula (II): wherein the dashed line indicates attachment to a nitrogen of -D by forming an amide bond; -X- is selected from the group consisting of -C(R 4 R 4a )-; -N(R 4 )-; -0-;
  • X 1 is selected from the group consisting of C and S(O);
  • -X 2 - is selected from the group consisting of -C(R 8 R 8a )- and -C(R 8 R 8a )-C(R 9 R 9a )-;
  • -R 1 , -R la , -R 2 , -R 2a , -R 4 , -R 4a , -R 5 , -R 5a , -R 6 , -R 8 , -R 8a , -R 9 , -R 9a are independently selected from the group consisting of -H; and Ci- 6 alkyl;
  • -R 3 , -R 3a are independently selected from the group consisting of -H; and Ci- 6 alkyl, provided that in case one of -R 3 , -R 3a or both are other than -H they are connected to N to which they are attached through an SP 3 -hybridized carbon atom;
  • -R 7a , -R 10 , -R 10a , -R 11 are independently of each other selected from the group consisting of -H and Ci -6 alkyl; optionally, one or more of the pairs -R la /-R 4a , -R la /-R 5a , -R la /-R 7a , -R 4a /-R 5a , -R 8a /-R 9a form a chemical bond; optionally, one or more of the pairs -R’/-R la , -R 2 /-R 2a , -R 4 /-R 4a , -R 5 /-R 5a , -R 8 /-R 8a ,
  • -R 9 /-R 9a are joined together with the atom to which they are attached to form a C3-10 cycloalkyl or 3- to 10-membered heterocyclyl; optionally, one or more of the pairs -RV-R 4 , -RV-R 5 , -RV-R 6 , -R’/-R 7a , -R 4 /-R 5 , -R 4 /-R 6 , -R 8 /-R 9 , -R 2 /-R 3 are joined together with the atoms to which they are attached to form a ring A; optionally, R 3 /R 3a are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle; A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8
  • -L 1 - of formula (II) is substituted with one moiety -L 2 -Z.
  • R # and R ## represent an sp 3 -hydridized carbon atom.
  • Exemplary embodiments of suitable 3- to 10-membered heterocycles formed by -R 3 /-R 3a of formula (II) together with the nitrogen atom to which they are attached are the following: wherein dashed lines indicate attachment to the rest of the molecule; and -R is selected from the group consisting of -H and Ci- 6 alkyl.
  • the moiety -L 1 - of formula (II) may optionally be further substituted.
  • any substituent may be used as far as the cleavage principle is not affected, i.e. the hydrogen marked with the asterisk in formula (II) is not replaced and the nitrogen of the moiety
  • R 3a ' of formula (II) remains part of a primary, secondary or tertiary amine, i.e. -R 3 and -R 3a are independently of each other -H or are connected to -N ⁇ through an sp 3 -hybridized carbon atom.
  • -R 1 or -R la of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -R 2 or -R 2a of formula (II) is substituted with -L 2 -Z or -L 2 -Z’ .
  • -R 3 or -R 3a of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -R 4 of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -R 5 or -R 5a of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -R 6 of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -R 7 or -R 7a of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -R 8 or -R 8a of formula (II) is substituted with -L 2 -Z or -L 2 -Z’ .
  • -R 9 or -R 9a of formula (II) is substituted with -L 2 -Z or -L 2 -Z’.
  • -L 1 - has a structure as disclosed in WO2016/020373 Al. Accordingly, in certain embodiments the moiety -L 1 - is of formula (III): wherein the dashed line indicates attachment to a primary or secondary amine or hydroxyl of -D by forming an amide or ester linkage, respectively;
  • Ci- 6 alkyl is optionally substituted with one or more halogen, which are the same or different; each -R 12 , -R 12a , -R 13 , -R 13a , -R 13b is independently selected from the group consisting of -H, and Ci- 6 alkyl; wherein Ci- 6 alkyl is optionally substituted with one or more halogen, which are the same or different; optionally, one or more of the pairs -R'/-R la , -R 2 /-R 2a , -R 3 /-R 3a , -R 6 /-R 6a , -R 7 /-R 7a are joined together with the atom to which they are attached to form a C3-10 cycloalkyl or a 3- to 10- membered heterocyclyl; optionally, one or more of the pairs -RV-R 2 ,
  • -R 3 /-R 6 , -R 3 /-R 7 , -R 4 /-R 5 , -R 4 /-R 6 , -R 4 /-R 7 , -R 5 /-R 6 , -R 5 /-R 7 , -R 6 /-R 7 are joint together with the atoms to which they are attached to form a ring A;
  • A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-membered heterobicyclyl; wherein -L 1 - is substituted with at least one -L 2 -Z and wherein -L 1 - is optionally further substituted.
  • -L 1 - of formula (III) is substituted with one moiety -L 2 -Z. In one embodiment -L 1 - of formula (III) is not further substituted.
  • -L 1 - has a structure as disclosed in EP1536334B1, W02009/009712A1, W02008/034122A1, WO2009/143412A2, WO2011/082368A2, and US8618124B2, which are herewith incorporated by reference.
  • -L 1 - has a structure as disclosed in US8946405B2 and US8754190B2. Accordingly, in certain embodiments -L 1 - is of formula (IV):
  • -R 3 is selected from the group consisting of -H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR 9 and -N(R 9 )2;
  • -R 4 is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each -R 5 is independently selected from the group consisting of -H, optionally substituted alkyl, optionally substituted alkenylalkyl, optionally substituted alkynylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; -R 9 is selected from the group consisting of -H and optionally substituted alkyl;
  • -Y- is absent and -X- is selected from the group consisting of -O- and -S-; or -Y- is -N(Q)CH2- and -X- is -O-;
  • Q is selected from the group consisting of optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; optionally, -R 1 and -R 2 may be joined to form a 3 to 8-membered ring; and optionally, both -R 9 together with the nitrogen to which they are attached form a heterocyclic ring; wherein -L 1 - is substituted with -L 2 -Z and wherein -L 1 - is optionally further substituted.
  • alkyl as used herein includes linear, branched or cyclic saturated hydrocarbon groups of 1 to 8 carbons, or in some embodiments 1 to 6 or 1 to 4 carbon atoms.
  • alkoxy includes alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, cyclobutoxy, and similar.
  • alkenyl includes non-aromatic unsaturated hydrocarbons with carbon-carbon double bonds.
  • alkynyl includes non-aromatic unsaturated hydrocarbons with carbon-carbon triple bonds.
  • aryl includes aromatic hydrocarbon groups of 6 to 18 carbons, preferably 6 to 10 carbons, including groups such as phenyl, naphthyl, and anthracenyl.
  • heteroaryl includes aromatic rings comprising 3 to 15 carbons containing at least one N, O or S atom, preferably 3 to 7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, indenyl, and similar.
  • alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkylene linkage.
  • the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.
  • halogen includes bromo, fluoro, chloro and iodo.
  • heterocyclic ring refers to a 4 to 8 membered aromatic or non-aromatic ring comprising 3 to 7 carbon atoms and at least one N, O, or S atom.
  • Examples are piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term “heteroaryl” above.
  • suitable substituents are selected from the group consisting of alkyl, alkenyl, alkynyl, or an additional ring, each optionally further substituted.
  • Optional substituents on any group, including the above, include halo, nitro, cyano, -OR, -SR, -NR 2 , -OCOR, -NRCOR, -COOR, -CONR 2 , -SOR, -S0 2 R, -SONR 2 , -S0 2 NR 2 , wherein each R is independently alkyl, alkenyl, alkynyl, aryl or heteroaryl, or two R groups taken together with the atoms to which they are attached form a ring.
  • -L 1 - of formula (IV) is substituted with one moiety -L 2 -Z.
  • -L 1 - of formula (IV) is not further substituted.
  • -L 1 - has a structure as disclosed in WO2013/036857A1. Accordingly, in certain embodiments -L 1 - is of formula (V): wherein the dashed line indicates attachment to -D through an amine functional group of -D; -R 1 is selected from the group consisting of optionally substituted linear, branched, or cyclic alkyl; optionally substituted aryl; optionally substituted heteroaryl; alkoxy; and -NR 5 2; -R 2 is selected from the group consisting of -H; optionally substituted C 1 -C 6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl;
  • -R 3 is selected from the group consisting of -H; optionally substituted C 1 -C 6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl;
  • -R 4 is selected from the group consisting of -H; optionally substituted C 1 -C 6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; each -R 5 is independently of each other selected from the group consisting of -H; optionally substituted C 1 -C 6 alkyl; optionally substituted aryl; and optionally substituted heteroaryl; or when taken together two -R 5 can be cycloalkyl or cyclohetero alkyl; wherein -L 1 - is substituted with -L 2 -Z and wherein -L 1 - is optionally further substituted.
  • Alkyl “alkenyl”, and “alkynyl” include linear, branched or cyclic hydrocarbon groups of 1-8 carbons or 1-6 carbons or 1-4 carbons wherein alkyl is a saturated hydrocarbon, alkenyl includes one or more carbon-carbon double bonds and alkynyl includes one or more carbon-carbon triple bonds. Unless otherwise specified these contain 1-6 C.
  • Aryl includes aromatic hydrocarbon groups of 6-18 carbons, preferably 6-10 carbons, including groups such as phenyl, naphthyl, and anthracene
  • Heteroaryl includes aromatic rings comprising 3- 15 carbons containing at least one N, O or S atom, preferably 3-7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiszolyl, isothiazolyl, quinolyl, indolyl, indenyl, and similar.
  • substituted means an alkyl, alkenyl, alkynyl, aryl, or heteroaryl group comprising one or more substituent groups in place of one or more hydrogen atoms.
  • Substituents may generally be selected from halogen including F, Cl, Br, and I; lower alkyl including linear, branched, and cyclic; lower haloalkyl including fluoroalkyl, chloroalkyl, bromoalkyl, and iodoalkyl; OH; lower alkoxy including linear, branched, and cyclic; SH; lower alkylthio including linear, branched and cyclic; amino, alkylamino, dialkylamino, silyl including alkylsilyl, alkoxysilyl, and arylsilyl; nitro; cyano; carbonyl; carboxylic acid, carboxylic ester, carboxylic amide, aminocarbonyl; aminoacyl; carbamate; urea;
  • -L 1 - of formula (V) is substituted with one moiety -L 2 -Z.
  • -L 1 - has a structure as disclosed in US7585837B2. Accordingly, in certain embodiments -L 1 - is of formula (VI): wherein the dashed line indicates attachment to -D through an amine functional group of -D;
  • R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, alkoxyalkyl, aryl, alkaryl, aralkyl, halogen, nitro, -SO3H, -SO2NHR 5 , amino, ammonium, carboxyl, PO3H2, and OPO3H2;
  • R 3 , R 4 , and R 5 are independently selected from the group consisting of hydrogen, alkyl, and aryl; wherein -L 1 - is substituted with -L 2 -Z and wherein -L 1 - is optionally further substituted.
  • Suitable substituents for formula (VI) are alkyl (such as C 1 - 6 alkyl), alkenyl (such as C2-6 alkenyl), alkynyl (such as C2-6 alkynyl), aryl (such as phenyl), heteroalkyl, heteroalkenyl, heteroalkynyl, heteroaryl (such as aromatic 4 to 7 membered heterocycle) or halogen moieties. Only in the context of formula (VI) the terms used have the following meaning:
  • alkyl alkoxy, alkoxyalkyl, aryl, “alkaryl” and “aralkyl” mean alkyl radicals of 1- 8, preferably 1-4 carbon atoms, e.g. methyl, ethyl, propyl, isopropyl and butyl, and aryl radicals of 6- 10 carbon atoms, e.g. phenyl and naphthyl.
  • halogen includes bromo, fluoro, chloro and iodo.
  • -L 1 - of formula (VI) is substituted with one moiety -L 2 -Z. In certain embodiments -L 1 - of formula (VI) is not further substituted.
  • -L 1 - has a structure as disclosed in W02002/089789A1. Accordingly, in certain embodiments -L 1 - is of formula (VII):
  • Yi and Y2 are independently O, S or NR 7 ;
  • R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are independently selected from the group consisting of hydrogen, Ci-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C 1 - 6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, Ci- 6 heteroalkyls, substituted C 1 - 6 heteroalkyls, Ci - 6 alkoxy, phenoxy, and Ci- 6 heteroalkoxy;
  • Ar is a moiety which when included in formula (VII) forms a multisubstituted aromatic hydrocarbon or a multi-substituted heterocyclic group;
  • X is a chemical bond or a moiety that is actively transported into a target cell, a hydrophobic moiety, or a combination thereof, y is 0 or 1; wherein -L 1 - is substituted with -L 2 -Z and wherein -L 1 - is optionally further substituted. Only in the context of formula (VII) the terms used have the following meaning:
  • alkyl shall be understood to include, e.g. straight, branched, substituted Ci-12 alkyls, including alkoxy, C3-8 cycloalkyls or substituted cycloalkyls, etc.
  • Substituted shall be understood to include adding or replacing one or more atoms contained within a functional group or compounds with one or more different atoms.
  • Substituted alkyls include carboxyalkyls, aminoalkyls, dialkylaminos, hydroxyalkyls and mercaptoalkyls; substtued cycloalkyls include moieties such as 4-chlorocyclohexyl; aryls include moieties such as napthyl; substituted aryls include moieties such as 3-bromo-phenyl; aralkyls include moieties such as toluyl; heteroalkyls include moieties such as ethylthiophene; substituted heteroalkyls include moieties such as 3-methoxythiophone; alkoxy includes moieities such as methoxy; and phenoxy includes moieties such as 3-nitrophenoxy.
  • Halo- shall be understood to include fluoro, chloro
  • -L 1 - of formula (VII) is substituted with one moiety -L 2 -Z. In certain embodiments -L 1 - of formula (VII) is not further substituted.
  • -L 1 - comprises a substructure of formula (VIII) wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D by forming an amide bond; the unmarked dashed lines indicate attachment to the remainder of -L 1 -; and wherein -L 1 - is substituted with -L 2 -Z and wherein -L 1 - is optionally further substituted.
  • -L 1 - of formula (VIII) is substituted with one moiety -L 2 -Z.
  • -L 1 - of formula (VIII) is not further substituted.
  • -L 1 - comprises a substructure of formula (IX) wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D by forming a carbamate bond; the unmarked dashed lines indicate attachment to the remainder of -L 1 -; and wherein -L 1 - is substituted with -L 2 -Z and wherein -L 1 - is optionally further substituted.
  • -L 1 - of formula (IX) is substituted with one moiety -L 2 -Z. In certain embodiments -L 1 - of formula (IX) is not further substituted.
  • -L 1 - is of formula (IX-a): wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D and the unmarked dashed line indicates attachment to -L 2 -Z; n is 0, 1, 2, 3 or 4;
  • -Y2- and -Y3- are independently selected from the group consisting of -O- and -S-;
  • -Y4- is selected from the group consisting of -O-, -NR 5 - and -C(R 6 R 6a )-; -R 3 , -R 5 , -R 6 and -R 6a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2- methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl,
  • -R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl,
  • -W- is selected from the group consisting of C 1 - 2o alkyl optionally interrupted by one or more groups selected from the group consisting of C3-10 cycloalkyl, 8- to 30-membered carbopolycyclyl, 3- to 10-membered heterocyclyl, -C(O)-, -C(O)N(R 7 )-, -0-, -S- and -N(R 7 )-;
  • -Nu is a nucleophile selected from the group consisting of -N(R 7 R 7a ), -N(R 7 OH), -N(R 7 )-N(R 7a R 7b ), -S(R 7 ),-COOH,
  • -Ar- is selected from the group consisting of
  • -Z 1 - is selected from the group consisting of -0-, -S- and -N(R 7 )-, and
  • -R 7 , -R 7a and-R 7b are independently selected from the group consisting of -H, Ci- 6 alkyl, C2-6 alkenyl and C2-6 alkynyl; and wherein -L 1 - is optionally further substituted.
  • -D is attached to -L 1 - of formula (IX-a) through the nitrogen of an amine functional group of -D, such as to the nitrogen of the amine functional group of a lysine side chain of -D.
  • -L 1 - of formula (IX-a) is substituted with one moiety -L 2 2 -Z.
  • -L - is of formula (IX-b): wherein the dashed line marked with the asterisk indicates attachment to a nitrogen of -D and the unmarked dashed line indicates attachment to -L 2 -Z; n is 0, 1, 2, 3, or 4;
  • -Y2- and -Y3- are independently selected from the group consisting of -O- and -S-;
  • -Y4- is selected from the group consisting of -O-, -NR 5 - and -C(R 6 R 6a )-;
  • -R 2 , -R 3 , -R 5 , -R 6 , -R 6a are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2- methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2- dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl;
  • -R 4 is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2- methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl;
  • -W- is selected from the group consisting of C 1 - 2o alkyl optionally interrupted by one or more groups selected from the group consisting of C3-10 cycloalkyl, 8- to 30-membered carbopolycyclyl, 3- to 10-membered heterocyclyl, -C(O)-, -C(O)N(R 7 )-, -O-, -S- and -N(R 7 )-; -
  • -Ar- is selected from the group consisting of
  • -Z 1 - is selected from the group consisting of -0-, -S- and -N(R 7 )-, and -Z 2 -is -N(R 7 )-;
  • -R 7 , -R 7a , -R 7b are independently of each other selected from the group consisting of -H, Ci- 6 alkyl, C2-6 alkenyl and C2-6 alkynyl; and wherein -L 1 - is optionally further substituted.
  • -D is attached to -L 1 - of formula (IX-b) through the nitrogen of an amine functional group of -D, such as to the nitrogen of the amine functional group of a lysine side chain of-D.
  • -L 1 - of formula (IX-b) is substituted with one moiety -L 2 -Z.
  • -L 1 - of formula (IX-b) is not further substituted.
  • -Y 2 - of formula (IX-a) and (IX-b) is -0-.
  • -Y 3 - of formula (IX-a) and (IX-b) is -0-.
  • -Y 4 - of formula (IX-a) and (IX-b) is -NR 5 -.
  • Y 5 of formula (IX-a) and (IX-b) 0.
  • n of formula (IX-a) and (IX-b) is 0 or 1. In certain embodiments n of formula (IX-a) and (IX-b) is 0. In certain embodiments n of formula (IX-a) and (IX-b) is 1.
  • -R 2 of formula (IX-b) is selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl. In certain embodiments -R 2 of formula (IX-b) is selected from the group consisting of -H, methyl, ethyl, n-propyl and isopropyl. In certain embodiments -R 2 of formula (IX-b) is selected from -H, methyl and ethyl. In certain embodiments -R 2 of formula (IX-b) is -H.
  • -R 3 of formula (IX-a) and (IX-b) is selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • -R 3 of formula (IX-a) and (IX-b) is selected from the group consisting of -H, methyl, ethyl, n-propyl and isopropyl.
  • -R 3 of formula (IX-a) and (IX-b) is selected from -H, methyl and ethyl.
  • -R 3 of formula (IX-a) and (IX-b) is -H.
  • each -R 4 of formula (IX-a) and (IX-b) is independently selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • -R 4 of formula (IX-a) and (IX-b) is selected from the group consisting of methyl, ethyl, n-propyl and isopropyl.
  • -R 4 of formula (IX-a) and (IX-b) is selected from methyl and ethyl.
  • -R 5 of formula (IX-a) and (IX-b) is selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • -R 5 of formula (IX-a) and (IX-b) is selected from the group consisting of -H, methyl, ethyl, n-propyl and isopropyl.
  • -R 5 of formula (IX-a) and (IX-b) is selected from methyl and ethyl.
  • -R 5 of formula (IX-a) and (IX-b) is methyl.
  • -R 6 and -R 6a of formula (IX-a) and (IX-b) are independently selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert- butyl.
  • -R 6 and -R 6a of formula (IX-a) and (IX-b) are independently selected from the group consisting of -H, methyl, ethyl, n-propyl and isopropyl.
  • -R 6 and -R 6a of formula (IX-a) and (IX-b) are independently selected from -H, methyl and ethyl. In certain embodiments -R 6 and -R 6a of formula (IX-a) and (IX-b) are both -H.
  • Ar of formula (IX-a) and (IX-b) is phenyl. In certain embodiments Ar of formula (IX-a) and (IX-b) is wherein the dashed lines indicate attachment to the remainder of the moiety of formula (IX-a) and (IX-b).
  • W of formula (IX-a) and (IX-b) is C 1 - 2o alkyl, optionally interrupted with C 3-10 cycloalkyl, -C(O)-, -C(O)N(R 7 )-, -0-, -S- and -N(R 7 )-.
  • W of formula (IX-a) and (IX-b) is CM O alkyl, optionally interrupted with C 3-10 cycloalkyl, -C(O)-, -C(O)N(R 7 )-, -0-, -S- and -N(R 7 )-.
  • W of formula (IX-a) and (IX-b) is Ci-6 alkyl, optionally interrupted with C3- 10 cycloalkyl, -C(O)-, -C(O)N(R 7 )-, -0-, -S- and -N(R 7 )-.
  • W of formula (IX-a) and (IX-b) is wherein the dashed lines indicate attachment to the remainder of the moiety of formula (IX-a) or (IX- b), respectively.
  • -Nu of formula (IX-a) and (IX-b) is -N(R 7 R 7a ).
  • -R 7 , -R 7a and -R 7b of formula (IX-a) and (IX-b) are independently of each other selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert-butyl.
  • -R 7 , -R 7a and -R 7b of formula (IX-a) and (IX-b) are independently of each other selected from -H, methyl, ethyl, n-propyl and isopropyl.
  • -R 7 , -R 7a and -R 7b of formula (IX-a) and (IX-b) are independently of each other selected from methyl or ethyl. In certain embodiments -R 7 , -R 7a and -R 7b of formula (IX-a) and (IX-b) are both methyl.
  • -D is attached to -L 1 - of formula (IX-c) through the nitrogen of an amine functional group of -D, such as to the nitrogen of the amine functional group of a lysine side chain of-D.
  • si of formula (IX-c) is an integer selected from the group consisting of 1, 2, 3, 4 and 5. In certain embodiments si of formula (IX-c) is 1. In certain embodiments si of formula (IX-c) is 2. In certain embodiments si of formula (IX-c) is 3. In certain embodiments si of formula (IX-c) is 4. In certain embodiments si of formula (IX-c) is 5.
  • dashed line marked with the asterisk indicates attachment to a nitrogen of -D; and the unmarked dashed line indicates attachment to -L 2 -Z.
  • -D is attached to -L 1 - of formula (IX-d) through the nitrogen of an amine functional group of -D, such as to the nitrogen of the amine functional group of a lysine side chain of-D.
  • -L 1 - has a structure as disclosed in W02020/206358 Al. Accordingly, in certain embodiments the moiety -L 1 - is of formula (X): wherein the unmarked dashed line indicates attachment to -D; the dashed line marked with the asterisk indicates attachment to -L 2 -Z or -L 2 -Z’; n is an integer selected from the group consisting of 0, 1, 2, 3, 4, 5 and 6;
  • -R 1 and -R 2 are independently an electron-withdrawing group, alkyl, or -H, and wherein at least one of -R 1 or -R 2 is an electron-withdrawing group; each -R 4 is independently C1-C3 alkyl or the two -R 4 are taken together with the carbon atom to which they are attached to form a 3- to 6-membered ring; and
  • -Y- is absent when -D is a drug moiety connected through an amine, or -Y- is -N(R 6 )CH2- when -D is a drug moiety connected through a phenol, alcohol, thiol, thiophenol, imidazole, or non-basic amine; wherein -R 6 is optionally substituted C ⁇ -Ce alkyl, optionally substituted aryl, or optionally substituted heteroaryl.
  • -L 1 - of formula (X) is substituted with one moiety -L 2 -Z.
  • n of formula (X) is an integer selected from 1, 2, 3, 4, 5 and 6. In certain embodiments n of formula (X) is an integer selected from 1, 2 and 3. In certain embodiments n of formula (X) is an integer from 0, 1, 2 and 3. In certain embodiments n of formula (X) is 1. In certain embodiments n of formula (X) is 2. In certain embodiments n of formula (X) is 3.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is selected from the group consisting of -CN; -NO2; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted alkenyl; optionally substituted alkynyl; -COR 3 , -SOR 3 , or -SO2R 3 , wherein -R 3 is -H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR 8 or -NR 8 2, wherein each -R 8 is independently -H or optionally substituted alkyl, or both -R 8 groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring; or -SR 9 , wherein -R 9 is optionally substituted alkyl, optionally substituted aryl, optionally substituted arylal
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is -CN. In certain embodiments the electron-withdrawing group of -R 1 and -R 2 of formula (X) is -NO2. In certain embodiments the electron-withdrawing group of -R 1 and -R 2 of formula (X) is optionally substituted aryl comprising 6 to 10 carbons. In certain embodiments the electron- withdrawing group of -R 1 and -R 2 of formula (X) is optionally substituted phenyl, naphthyl, or anthracenyl.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is optionally substituted heteroaryl comprising 3 to 7 carbons and comprising at least one N, O, or S atom.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is optionally substituted pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, or indenyl.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is optionally substituted alkenyl containing 2 to 20 carbon atoms. In certain embodiments the electron-withdrawing group of -R 1 and -R 2 of formula (X) is optionally substituted alkynyl comprising 2 to 20 carbon atoms.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is -COR 3 , -SOR 3 , or -SO2R 3 , wherein -R 3 is -H, optionally substituted alkyl comprising 1 to 20 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR 8 or -NR 8 2, wherein each -R 8 is independently -H or optionally substituted alkyl comprising 1 to 20 carbon atoms, or both -R 8 groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (X) is -SR 9 , wherein -R 9 is optionally substituted alkyl comprising 1 to 20 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl.
  • At least one of -R 1 or -R 2 of formula (X) is -CN, -SOR 3 or -SO2R 3 . In certain embodiments at least one of -R 1 and -R 2 of formula (X) is -CN or -SO2R 3 . In certain embodiments at least one of -R 1 and -R 2 of formula (X) is -CN or -SO2R 3 , wherein -R 3 is optionally substituted alkyl, optionally substituted aryl, or -NR 8 2.
  • At least one of -R 1 and -R 2 of formula (X) is -CN, -S0 2 N(CH 3 ) 2 , -SO2CH3, phenyl substituted with -SO2, phenyl substituted with -S0 2 and -Cl, -S0 2 N(CH 2 CH 2 ) 2 0, -S0 2 CH(CH 3 ) 2 , -S0 2 N(CH 3 )(CH 2 CH 3 ), or -S0 2 N(CH 2 CH 2 OCH 3 ) 2 .
  • each -R 4 of formula (X) is independently C1-C3 alkyl. In certain embodiments both -R 4 are methyl.
  • -Y- of formula (X) is absent. In certain embodiments -Y- of formula (X) is -N(R 6 )CH 2 -.
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -CN, -R 2 is -H, and -R 4 is -CH 3 .
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -S0 2 N(CH 3 ) 2 , -R 2 is -H, and -R 4 is -CH 3 .
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is S0 2 CH 3 , -R 2 is -H, and -R 4 is -CH 3 .
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -S0 2 N(CH 2 CH 2 ) 2 CHCH 3 , -R 2 is -H, and -R 4 is -CH 3 .
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is phenyl substituted with -S0 2 , -R 2 is -H, and -R 4 is -CH 3 .
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is phenyl substituted with -SO2 and -Cl, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -S0 2 N(CH 2 CH 2 ) 2 0, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -S0 2 CH(CH3) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -S0 2 N(CH 3 )(CH 2 CH 3 ), -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is -S0 2 N(CH 2 CH 2 OCH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 1, -R 1 is phenyl substituted with-S0 2 and -CH3, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -CN, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -S0 2 N(CH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is S0 2 CH 3 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -S0 2 N(CH 2 CH 2 ) 2 CHCH 3 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is phenyl substituted with -S0 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is phenyl substituted with -S0 2 and -Cl, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -S0 2 N(CH 2 CH 2 ) 2 0, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -S0 2 CH(CH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -S0 2 N(CH3)(CH 2 CH3), -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is -S0 2 N(CH 2 CH 2 OCH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 2, -R 1 is phenyl substituted with -S0 2 and -CH3, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -CN, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -S0 2 N(CH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is S0 2 CH 3 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -S0 2 N(CH 2 CH 2 ) 2 CHCH3, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is phenyl substituted with -S0 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is phenyl substituted with -S0 2 and -Cl, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -S0 2 N(CH 2 CH 2 ) 2 0, -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -S0 2 CH(CH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -S0 2 N(CH3)(CH 2 CH3), -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is -S0 2 N(CH 2 CH 2 OCH 3 ) 2 , -R 2 is -H, and -R 4 is -CH3.
  • -L 1 - is of formula (X), wherein n is 3, -R 1 is phenyl substituted with -S0 2 and -CH3, -R 2 is -H, and -R 4 is -CH3.
  • alkyl refers to linear, branched, or cyclic saturated hydrocarbon groups of 1 to 20, 1 to 12, 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
  • an alkyl is linear or branched.
  • linear or branched alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t- butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, and n-decyl.
  • an alkyl is cyclic.
  • cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, and cyclohexyl.
  • alkoxy refers to alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, and cyclobutoxy.
  • alkenyl refers to non-aromatic unsaturated hydrocarbons with carbon-carbon double bonds and 2 to 20, 2 to 12, 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
  • alkynyl refers to non-aromatic unsaturated hydrocarbons with carbon-carbon triple bonds and 2 to 20, 2 to 12, 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
  • aryl refers to aromatic hydrocarbon groups of 6 to 18 carbons, preferably 6 to 10 carbons, including groups such as phenyl, naphthyl, and anthracenyl.
  • heteroaryl refers to aromatic rings comprising 3 to 15 carbons comprising at least one N, O or S atom, preferably 3 to 7 carbons comprising at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, and indenyl.
  • alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkyl linkage.
  • the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.
  • halogen refers to bromo, fluoro, chloro and iodo.
  • heterocyclic ring refers to a 3- to 15-membered aromatic or nonaromatic ring comprising at least one N, O, or S atom.
  • examples include piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term "heteroaryl” above.
  • a heterocyclic ring or heterocyclyl is nonaromatic.
  • a heterocyclic ring or heterocyclyl is aromatic.
  • all moieties -L 2 - of the conjugate are identical, provided there is more than one moiety -L 2 - present in the conjugate.
  • the conjugate of the present invention comprises more than one type of -L 2 -, such as two, three, four or five different moieties -L 2 -. Such more than one type of -L 2 - may be connected to only one type of -L 1 - or may be connected to more than one type of -L 1 -.
  • -L 2 - is a chemical bond.
  • -L 2 - is a spacer moiety.
  • -L 2 - is selected from the group consisting of -T'-, -C(O)0-, -0-, -C(O)-, -C(O)N(R y1 )-, -S(O) 2 N(R y1 )-, -S(O)N(R y1 )-, -S(O) 2 -, -S(O)-, -N(R yl )S(O) 2 N(R yla )-, -S-, -N(R y1 )-, -OC(OR yl )(R yla )-, -N(R yl )C(O)N(R yla )-, -0C(O)N(R y1 )-, Ci-so alkyl, C 2.50 alkenyl and C 2-5o alkynyl; wherein -T ' -, C 1-50 alkyl
  • -R yl and -R yla are independently selected from the group consisting of -H, -T', C 1-50 alkyl, C 2 -5o alkenyl and C 2-5o alkynyl; wherein -T ' , C 1-50 alkyl, C 2-5o alkenyl and C 2-5o alkynyl are optionally substituted with one or more -R y2 , which are the same or different, and wherein C 1-50 alkyl, C 2 -50 alkenyl and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T'-, -C(O)0-, -0-, -C(O)-, -C(O)N(R y4 )-, -S(O) 2 N(R y4 )-, -S(O)N(R y4 )-, -S(O) 2 -, -S(O)-, -
  • each -R y3 , -R y3a , -R y4 , -R y4a , -R y5 , -R y5a and -R y5b is independently selected from the group consisting of -H and Ci- 6 alkyl; wherein Ci- 6 alkyl is optionally substituted with one or more halogen, which are the same or different.
  • -L 2 - is selected from the group consisting of -T'-, -C(O)0-, -0-, -C(O)-, -C(O)N(R y1 )-, -S(O) 2 N(R y1 )-, -S(O)N(R y1 )-, -S(O) 2 -, -S(O)-, -N(R yl )S(O) 2 N(R yla )-, -S-, -N(R y1 )-, -OC(OR yl )(R yla )-, -N(R yl )C(O)N(R yla )-, -0C(O)N(R y1 )-, CMO alkyl, C 2-50 alkenyl, and C 2 -5o alkynyl; wherein -T'-, C 1 - 2o alkyl, C
  • -R yl and -R yla are independently selected from the group consisting of -H, -T', Ci-10 alkyl, C 2-i o alkenyl, and C 2 -io alkynyl; wherein -T', CM O alkyl, C 2 -io alkenyl, and C 2 -io alkynyl are optionally substituted with one or more -R y2 , which are the same or different, and wherein CM O alkyl, C2-10 alkenyl, and C 2 -io alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T'-, -C(O)0-, -0-, -C(O)-, -C(O)N(R y4 )-, -S(O) 2 N(R y4 )-, -S(O)N(R y4 )-, -S(O) 2 -, -
  • -L 2 - is selected from the group consisting of -T'-, -C(O)0-, -0-, -C(O)-, -C(O)N(R y1 )-, -S(O) 2 N(R y1 )-, -S(O)N(R y1 )-, -S(O) 2 -, -S(O)-, -N(R yl )S(O) 2 N(R yla )-, -S-, -N(R y1 )-, -OC(OR yl )(R yla )-, -N(R yl )C(O)N(R yla )-, -0C(O)N(R y1 )-, Ci.
  • Ci-so alkyl, C 2-5o alkenyl, and C 2-5o alkynyl are optionally substituted with one or more -R y2 , which are the same or different and wherein Ci-so alkyl, C 2 -50 alkenyl, and C 2 -50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T'-, -C(O)0-, -0-, -C(O)-, -C(O)N(R y3 )-, -S(O) 2 N(R y3 )-, -S(O)N(R y3 )-, -S(O) 2 -,
  • -R yl and -R yla are independently selected from the group consisting of -H, -T', CM O alkyl, C 2 -io alkenyl and C 2 -io alkynyl; each T' is independently selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8-to 30-membered carbopolycyclyl and 8- to 30-membered heteropolycyclyl; each -R y2 is independently selected from the group consisting of halogen, and Ci- 6 alkyl; and each -R y3 , -R y3a , -R y4 , -R y4a , -R y5 , -R y5a and -R y5b
  • -L 2 - is a C 1 - 2o alkyl chain, which is optionally interrupted by one or more groups independently selected from the group consisting of -0-, -T'- and -C(O)N(R y1 )-; and which C 1 - 2o alkyl chain is optionally substituted with one or more groups independently selected from the group consisting of -OH, -T' and -C(O)N(R y6 R y6a ); wherein -R yl , -R y6 , -R y6a are independently selected from the group consisting of H and CM alkyl and wherein T' is selected from the group consisting of phenyl, naphthyl, indenyl, indanyl, tetralinyl, C3-10 cycloalkyl, 3- to 10-membered heterocyclyl, 8- to 11-membered heterobicyclyl, 8- to 30-membered carbopol
  • -L 2 - has a molecular weight in the range of from 14 g/mol to 750 g/mol.
  • -L 2 - comprises a moiety selected from the group consisting of: wherein dashed lines indicate attachment to -L 1 -, the remainder of -L 2 - or Z, respectively; and -R and -R a are independently selected from the group consisting of -H, methyl, ethyl, n-propyl, isopropyl, n-buty, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2,2-dimethylpropyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl and 3,3-dimethylpropyl.
  • all moieties Z of the conjugate are identical, provided there is more than one moiety Z present in the conjugate.
  • the conjugate of the present invention comprises more than one type of Z, such as two, three, four or five different moieties Z. Such more than one type of Z may be connected to only one type of -L 2 - or may be connected to more than one type of -L 2 -.
  • Z is a fatty acid moiety, which is optionally substituted. In certain embodiments Z is an optionally substituted fatty acid moiety as disclosed in WO 2005/027978 A2 and WO 2014/060512 Al.
  • Z is a polymeric moiety i.e. a moiety that comprises at least one polymer, such as a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines),
  • Z is water-insoluble.
  • Z comprises a hydrogel.
  • Such hydrogel may be degradable or non- degradable, i.e. stable. In certain embodiments such hydrogel is degradable. In certain embodiments such hydrogel is non-degradable.
  • such hydrogel comprises one or more polymers selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly(anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyl
  • Z is a hydrogel as disclosed in as disclosed in W02006/003014, WO201 1/012715A1, WO2014/056926A1 or W02020/064846A1. In certain embodiments Z is a hydrogel as disclosed in WO2013/036847 A1.
  • Z is a hydrogel produced by a method comprising the step of reacting at least a first reactive polymer with a cleavable crosslinker compound, wherein said cleavable crosslinker compound comprises a first functional group -Y 1 that reacts with the first reactive polymer and further comprises a moiety that is cleaved by elimination under physiological conditions wherein said moiety comprises a second functional group -Y 2 that reacts with a second reactive polymer.
  • the cleavable crosslinker compound is of formula (PL-1) wherein m is O or l;
  • -X comprises a functional group capable of connecting to a reactive polymer that is amenable to elimination under physiological conditions and said second functional group -Y 2 ; at least one of -R 1 , -R 2 and -R 5 comprises said first functional group -Y 1 capable of connecting to a polymer; one and only one of -R 1 and -R 2 is selected from the group consisting of -H, alkyl, arylalkyl, and heteroarylalkyl; optionally, -R 1 and -R 2 may be joined to form a 3- to 8-membered ring; at least one or both of -R 1 and -R 2 is independently selected from the group consisting of -CN, -NO2, aryl, heteroaryl, alkenyl, alkynyl, -COR 3 , -SOR 3 , -SO2R 3 and -SR 4 ;
  • -R 3 is selected from the group consisting of -H, alkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, -OR 9 and -NR 9 2;
  • -R 4 is selected from the group consisting of alkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; each -R 5 is independently selected from the group consisting of -H, alkyl, alkenylalkyl, alkynylalkyl, (OCtbCfD p O-alkyl with p being an integer ranging from 1 to 1000, aryl, arylalkyl, heteroaryl and heteroarylalkyl; each -R 9 is independently selected from the group consisting of -H and alkyl or both -R 9 together with the nitrogen to which they are attached form a heterocyclic ring; and wherein the moiety of formula (PL-1) is optionally further substituted.
  • -X of formula (PL-1) is selected from the group consisting of succinimidyl carbonate, sulfosuccinimidyl carbonate halides, thioethers, esters, nitrophenyl carbonate, chloroformate, fluoroformate, optionally substituted phenols and formula (PL-2) wherein the dashed line indicates attachment to the remainder of formula (PL-1);
  • -T*- is selected from the group consisting of -O-, -S- and -NR 6 -; z is an integer selected from the group consisting of 1, 2, 3, 4, 5 and 6;
  • -X’- is absent or is selected from the group consisting of -OR 7 - and -SR 7 -;
  • -Y 2 is a functional group capable of connecting with a reactive polymer
  • -R 6 is selected from the group consisting of -H, alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl;
  • -R 7 is selected from the group consisting of alkylene, phenylene and (OCLLCPD p , with p being an integer ranging from 1 to 1000.
  • -X of formula (PL-1) comprises an activated carbonate such as succinimidyl carbonate, sulfosuccinimidyl carbonate, or nitrophenyl carbonate.
  • -X of formula (PL-1) has the formula (PL-2).
  • -X of formula (PL-1) is OR 7 or SR 7 , wherein R 7 is optionally substituted alkyl ene, optionally substituted phenylene or (OCH 2 CH 2 )p, wherein p is 1 to 1000.
  • p of formula (PL-2) is an integer ranging from 1 to 100. In certain embodiments p of formula (PL-2) is an integer ranging from 1 to 10.
  • -Y 1 of formula (PL-1) and -Y 2 of formula (PL-2) independently comprise N3, NH 2 , NH-CCVBU, SH, S l Bu, maleimide, C0 2 H, C0 2 l Bu, 1,3-diene, cyclopentadiene, furan, alkyne, cyclooctyne, acrylate or acrylamide, wherein l Bu is tert-butyl, and wherein when one of -Y 1 or -Y 2 comprises N3 the other does not comprise alkyne or cyclooctyne; when one of -Y 1 or -Y 2 comprises SH the other does not comprise maleimide, acrylate or acrylamide; when one of -Y 1 or -Y 2 comprises NH 2 the other does not comprise C0 2 H; when one of -Y 1 or -Y 2 comprises 1,3 -diene or cyclopentadiene the other does not comprise furan.
  • the cleavable crosslinker compound is of formula (PL-3) wherein m is 0 or 1; n is an integer selected from 1 to 1000; s is 0, 1 or 2; t is selected from the group consisting of 2, 4, 8, 16 and 32;
  • t of formula (PL-3) is 2. In certain embodiments t of formula (PL-3) is 4. In certain embodiments t of formula (PL-3) is 8. In certain embodiments t of formula (PL-3) is 16. In certain embodiments t of formula (PL-3) is 32.
  • -Q of formula (PL-3) has a structure selected from the group consisting of
  • -Q of formula (PL-3) has the structure of (PL-3-i). In certain embodiments -Q of formula (PL-3) has the structure of (PL-3-ii). In certain embodiments -Q of formula (PL-3) has the structure of (PL-3-iii).
  • -Y 1 of formula (PL-3) comprises N3, NH2, NH-CCVBu, SH, S’Bu, maleimide, CO2H, C0 2 l Bu, 1,3 -diene, cyclopentadiene, furan, alkyne, cyclooctyne, acrylate or acrylamide, wherein l Bu is tert-butyl.
  • each -Y 1 of formula (PL-1) or (PL-3) and -Y 2 of formula (PL-2) independently comprises N3, NH2, NH-CCVBu, SH, S l Bu, maleimide, CO2H, CCVBu, 1,3-diene, cyclopentadiene, furan, alkyne, cyclooctyne, acrylate or acrylamide.
  • one of -Y 1 and -Y 2 is azide and the other is a reactive functional group selected from the group consisting of acetylene, cyclooctyne, and maleimide.
  • one of-Y 1 and -Y 2 is thiol and the other is a reactive functional group selected from the group consisting of maleimide, acrylate, acrylamide, vinylsulfone, vinylsulfonamide, and halocarbonyl.
  • one of-Y 1 and -Y 2 is amine and the other is a selective reactive functional group selected from carboxylic acid and activated carboxylic acid.
  • one of-Y 1 and -Y 2 is maleimide and the other is a selective reactive functional group selected from the group consisting of 1,3 -diene, cyclopentadiene, and furan.
  • the first and any second polymer is selected from the group consisting of homopolymeric or copolymeric polyethylene glycols, polypropylene glycols, poly(N- vinylpyrrolidone), polymethacrylates, polyphosphazenes, polylactides, polyacrylamides, polyglycolates, polyethylene imines, agaroses, dextrans, gelatins, collagens, polylysines, chitosans, alginates, hyaluronans, pectins and carrageenans that either comprise suitable reactive functionalities or is of formula [Y 3 -(CH 2 ) s (CH 2 CH 2 0) n ] t Q, wherein -Y 3 is a reactive functional group, s is 0, 1 or 2, n is an integer selected from the group ranging from 10 to 1000, -Q is a core group having valency t, and t is an integer selected from the group consisting of 2, 4, 8, 16 and 32.
  • the first polymer comprises a multi-arm polymer. In certain embodiments the first polymer comprises at least three arms. In certain embodiments the first polymer comprises at least four arms. In certain embodiments the first polymer comprises at least five arms. In certain embodiments the first polymer comprises at least six arms. In certain embodiments the first polymer comprises at least seven arms. In certain embodiments the first polymer comprises at least eight arms.
  • the second polymer comprises a multi-arm polymer. In certain embodiments the second polymer comprises at least three arms. In certain embodiments the second polymer comprises at least four arms. In certain embodiments the second polymer comprises at least five arms. In certain embodiments the second polymer comprises at least six arms. In certain embodiments the second polymer comprises at least seven arms. In certain embodiments the second polymer comprises at least eight arms.
  • the first polymer comprises a 2-arm polyethylene glycol polymer. In certain embodiments the first polymer comprises a 4-arm polyethylene glycol polymer. In certain embodiments the first polymer comprises an 8-arm polyethylene glycol polymer. In certain embodiments the first polymer comprises a 16-arm polyethylene glycol polymer. In certain embodiments the first polymer comprises a 32-arm polyethylene glycol polymer.
  • the second polymer comprises a 2-arm polyethylene glycol polymer. In certain embodiments the second polymer comprises a 4-arm polyethylene glycol polymer. In certain embodiments the second polymer comprises an 8-arm polyethylene glycol polymer. In certain embodiments the second polymer comprises a 16-arm polyethylene glycol polymer. In certain embodiments the second polymer comprises a 32-arm polyethylene glycol polymer.
  • first and a second reactive polymer are reacted with said cleavable crosslinker compound, either sequentially or simultaneously.
  • first and second functional groups are the same.
  • the half-life of the reaction is between 1 and 5,000 hours, and more preferably between 1 and 1,000 hours, under physiological conditions of pH and temperature.
  • physiological conditions of pH and temperature is meant a pH of between 7 and 8 and a temperature between 30 and 40 degrees centigrade
  • reactive polymer and reactive oligomer refers to a polymer or oligomer comprising functional groups that are reactive towards other functional groups, most preferably under mild conditions compatible with the stability requirements of peptides, proteins, and other biomolecules.
  • Suitable functional groups found in reactive polymers include maleimides, thiols or protected thiols, alcohols, acrylates, acrylamides, amines or protected amines, carboxylic acids or protected carboxylic acids, azides, alkynes including cycloalkynes, 1,3 -dienes including cyclopentadienes and furans, alpha-halocarbonyls, and N-hydroxysuccinimidyl, N-hydroxysulfosuccinimidyl, or nitrophenyl esters or carbonates.
  • the term “functional group capable of connecting to a reactive polymer” refers to a functional group that reacts to a corresponding functional group of a reactive polymer to form a covalent bond to the polymer.
  • Suitable functional groups capable of connecting to a reactive polymer include maleimides, thiols or protected thiols, acrylates, acrylamides, amines or protected amines, carboxylic acids or protected carboxylic acids, azides, alkynes including cycloalkynes, 1,3-dienes including cyclopentadienes and furans, alpha-halocarbonyls, and N-hydroxysuccinimidyl, N- hydroxysulfosuccinimidyl, or nitrophenyl esters or carbonates.
  • substituted refers to an alkyl, alkenyl, alkynyl, aryl, or heteroaryl group comprising one or more substituent groups in place of one or more hydrogen atoms.
  • Substituent groups may generally be selected from halogen including F, Cl, Br, and I; lower alkyl including linear, branched, and cyclic; lower haloalkyl including fluoroalkyl, chloroalkyl, bromoalkyl, and iodoalkyl; OH; lower alkoxy including linear, branched, and cyclic; SH; lower alkylthio including linear, branched, and cyclic; amino, alkylamino, dialkylamino, silyl including alkylsilyl, alkoxysilyl, and arylsilyl; nitro; cyano; carbonyl; carboxylic acid, carboxylic ester, carboxylic amide; aminocarbonyl; aminoacyl; carbamate;
  • R 1 and R 2 may be modulated by the optional addition of electron-donating or electron-withdrawing substituents.
  • electron-donating group is meant a substituent resulting in a decrease in the acidity of the R 1 R 2 CH; electron-donating groups are typically associated with negative Hammett s or Taft s* constants and are well- known in the art of physical organic chemistry. (Hammett constants refer to aryl/heteroaryl substituents, Taft constants refer to substituents on non-aromatic moieties.)
  • suitable electron-donating substituents include lower alkyl, lower alkoxy, lower alkylthio, amino, alkylamino, dialkylamino, and silyl.
  • electron- withdrawing group refers to a substituent resulting in an increase in the acidity of the R 1 R 2 CH group; electron-withdrawing groups are typically associated with positive Hammett s or Taft s* constants and are well-known in the art of physical organic chemistry.
  • an alkoxy substituent on the ortho- or para-position of an aryl ring is electron-donating, and is characterized by a negative Hammett s constant
  • an alkoxy substituent on the meta-position of an aryl ring is electron- withdrawing and is characterized by a positive Hammett s constant.
  • alkyl alkenyl
  • alkynyl include linear, branched or cyclic hydrocarbon groups of 1 to 8 carbons or 1 to 6 carbons or 1 to 4 carbons wherein alkyl is a saturated hydrocarbon, alkenyl includes one or more carbon-carbon double bonds and alkynyl includes one or more carbon-carbon triple bonds. Unless otherwise specified these contain 1 to 6 carbons.
  • aryl includes aromatic hydrocarbon groups of 6 to 18 carbons, preferably 6 to 10 carbons, including groups such as phenyl, naphthyl, and anthracenyl.
  • Heteroaryl includes aromatic rings comprising 3 to 15 carbons containing at least one N, O or S atom, preferably 3 to 7 carbons containing at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, indenyl, and similar.
  • halogen includes fluoro, chloro, bromo and iodo.
  • maleimido is a group of the formula
  • Z is a hydrogel as disclosed in W02020/206358 Al.
  • Z is a hydrogel produced by a method comprising the steps of (a) providing a first prepolymer comprising a multi-arm polymer -P 2 , wherein said first prepolymer is of formula (PL-4) wherein n is an integer selected from 0, 1, 2, 3, 4, 5 and 6; r is an integer higher than 2;
  • -Y is a reactive functional group for connecting said first prepolymer to a second prepolymer
  • -R 1 and -R 2 are independently an electron-withdrawing group, alkyl, or -H, and wherein at least one of -R 1 and -R 2 is an electron-withdrawing group; each -R 4 is independently C1-C3 alkyl or the two -R 4 form together with the carbon atom to which they are attached a 3- to 6-membered ring;
  • -W- is absent or is wherein the dashed line marked with the asterisk indicates the attachment to -NH- and the unmarked dashed line indicates the attachment to -P 2 ; each of x, y, and z is independently an integer selected from 0, 1, 2, 3, 4, 5 and 6;
  • -B’ is -NPb, -ONH2, ketone, aldehyde, -SH, -OH, -CO2H, carboxamide group, or a group comprising a cyclooctyne or bicyclononyne;
  • -C* is carboxamide, thioether, thiosuccinimidyl, triazole, or oxime;
  • step (b) providing the second prepolymer comprising a multi-arm polymer -P 1 wherein each arm is terminated by a reactive functional group -Y” that reacts with -Y of step (a);
  • Z is a hydrogel obtainable from the method described above.
  • the hydrogel produced by the preceding method is degradable.
  • -Y and -Y react under step (c) to form an insoluble hydrogel matrix comprising crosslinks of formula (PL-4'): wherein n, r, -P 1 , -Y*-, -R 4 , -R 1 , -R 2 , -W- and -P 2 are as defined above.
  • n of formula (PL-4) or (PL-4') is an integer selected from 1, 2, 3, 4, 5 and 6. In certain embodiments n of formula (PL-4) or (PL-4') is an integer selected from 1, 2 and 3. In certain embodiments n of formula (PL-4) or (PL-4') is an integer selected from 0, 1, 2 and 3. In certain embodiments n of formula (PL-4) or (PL-4') is 1. In certain embodiments n of formula (PL-4) is 2. In certain embodiments n of formula (PL-4) or (PL-4') is 3.
  • the multi-arm -P 2 of formula (PL-4) or (PL-4') is an r-armed polymer, wherein r is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. In certain embodiments r of formula (PL-4) or (PL-4') is an integer selected from 2, 3, 4, 5, 6, 7 and 8. In certain embodiments r of formula (PL-4) or (PL-4') is an integer selected from 2, 4, 6 and 8. In certain embodiments r of formula (PL-4) or (PL-4') is 2. In certain embodiments r of formula (PL-4) or (PL-4') is 4. In certain embodiments r of formula (PL-4) or (PL-4') is 6. In certain embodiments r of formula (PL-4) or (PL- 4') is 8.
  • -P 2 of formula (PL-4) or (PL-4') has a molecular weight of at least 1 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 100 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 80 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 60 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 40 kDa.
  • -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 20 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 10 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of 1 to 5 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of about 20 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of about 40 kDa.
  • -P 2 of formula (PL-4) or (PL-4') has a molecular weight of about 60 kDa. In certain embodiments -P 2 of formula (PL-4) or (PL-4') has a molecular weight of about 80 kDa.
  • the multi-arm polymer -P 1 of step (b) is an r-armed polymer, wherein r is an integer selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12. In certain embodiments the multi-arm -P 1 of step (b) is an r-armed polymer, wherein r is an integer selected from 2, 3, 4, 5, 6, 7 and 8. In certain embodiments the multi-arm -P 1 of step (b) is an r-armed polymer, wherein r is an integer selected from 2, 4, 6 and 8. In certain embodiments the multi-arm -P 1 of step (b) is an r-armed polymer, wherein r is 2.
  • the multi-arm -P 1 of step (b) is an r-armed polymer, wherein r is 4. In certain embodiments the multi-arm -P 1 of step (b) is an r-armed polymer, wherein r is 6. In certain embodiments the multi-arm -P 1 of step (b) is an r-armed polymer, wherein r is 8. In certain embodiments -P 1 of step (b) has a molecular weight of at least 1 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 100 kDa.
  • the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 80 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 60 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 40 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 20 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 10 kDa.
  • the multi-arm polymer -P 1 of step (b) has a molecular weight of 1 to 5 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of about 20 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of about 40 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of about 60 kDa. In certain embodiments the multi-arm polymer -P 1 of step (b) has a molecular weight of about 80 kDa.
  • -P 1 of step (b) and -P 2 of formula (PL-4) or (PL-4') comprise poly( ethylene glycol) (PEG), poly( ethylene oxide) (PEO), poly(ethylene imine) (PEI), dextrans, hyaluronic acids, or co-polymers thereof.
  • -P 1 of step (b) and P 2 of formula (PL-4) or (PL-4') are PEG-based polymers.
  • -P 1 of step (b) and -P 2 of formula (PL-4) or (PL-4') are hyaluronic acid-based polymers.
  • -R 1 and -R 2 of formula (PL-4) or (PL-4') are independently electron- withdrawing groups, alkyl, or -H, and wherein at least one of -R 1 and -R 2 is an electron-withdrawing group.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -CN, -NO2 , optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkenyl, optionally substituted alkynyl, -COR 3 , -SOR 3 , or -SO2R 3 , wherein -R 3 is -H, optionally substituted alkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR 8 or -NR 8 2, wherein each -R 8 is independently -H or optionally substituted alkyl, or both -R 8 groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring; or -SR 9 , wherein -R 9 is optionally substituted alkyl, optionally substituted aryl, optionally substituted aryl
  • the electron-withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -CN. In certain embodiments the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -NO2. In certain embodiments the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is optionally substituted aryl containing 6 to 10 carbons. In certain embodiments the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is optionally substituted phenyl, naphthyl, or anthracenyl.
  • the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is optionally substituted heteroaryl comprising 3 to 7 carbons and containing at least one N, O, or S atom.
  • the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is optionally substituted pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, or indenyl.
  • the electron-withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is optionally substituted alkenyl containing 2 to 20 carbon atoms. In certain embodiments the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is optionally substituted alkynyl containing 2 to 20 carbon atoms.
  • the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -COR 3 , -SOR 3 , or -SO2R 3 , wherein R 3 is -H, optionally substituted alkyl containing 1 to 20 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -OR 8 or -NR 8 2, wherein each -R 8 is independently -H or optionally substituted alkyl containing 1 to 20 carbon atoms, or both -R 8 groups are taken together with the nitrogen to which they are attached to form a heterocyclic ring.
  • the electron- withdrawing group of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -SR 9 , wherein -R 9 is optionally substituted alkyl containing 1 to 20 carbon atoms, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl. In certain embodiments at least one of -R 1 and -R 2 is -CN or -SO2R 3 .
  • At least one of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -CN, -SOR 3 or -SO2R 3 . In certain embodiments at least one of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -CN or -SO2R 3 . In certain embodiments at least one of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -CN or -SO2R 3 , wherein -R 3 is optionally substituted alkyl, optionally substituted aryl, or -NR 8 2.
  • At least one of -R 1 and -R 2 of formula (PL-4) or (PL-4') is -CN, -SC>2N(CH3)2, -SO2CH3, phenyl substituted with -SO2, phenyl substituted with -SO2 and -Cl, -S0 2 N(CH 2 CH 2 )20, -S0 2 CH(CH 3 )2, -S0 2 N(CH 3 )(CH 2 CH3), or -S0 2 N(CH 2 CH 2 OCH3)2.
  • each -R 4 of formula (PL-4) or (PL-4') is independently C1-C3 alkyl or taken together may form a 3- to 6-membered ring. In certain embodiments each -R 4 of formula (PL-4) or (PL-4') is independently C1-C3 alkyl. In certain embodiments both -R 4 of formula (PL-4) or (PL-4') are methyl.
  • -Y and -Y are independently selected from the group consisting of amine, aminooxy, ketone, aldehyde, maleimidyl, thiol, alcohol, azide, 1,2,4,6-tetrazinyl, trans-cyclooctenyl, bicyclononynyl, cyclooctynyl, and protected variants thereof.
  • Y and Y" may react with each other such as in a selective way.
  • -Y is amine
  • -Y is carboxylic acid, active ester, or active carbonate to yield a residual connecting functional group -Y*- that is amide or carbamate.
  • -Y is azide
  • -Y is alkynyl, bicyclononynyl, or cyclooctynyl to yield a residual connecting functional group -Y*- that is 1,2, 3 -triazole.
  • -Y is NH2O
  • -Y” is ketone or aldehyde to yield a residual connecting functional group -Y*- that is oxime.
  • -Y is SH
  • -Y is maleimide or halocarbonyl to yield a residual connecting functional group -Y*- that is thiosuccinimidyl or thioether.
  • these roles of -Y and -Y” can be reversed to yield -Y*- of opposing orientation.
  • -Y*- comprises an amide, oxime, 1,2, 3 -triazole, thioether, thiosuccinimide, or ether. In certain embodiments -Y*- is -L 2 -.
  • conjugation reactions may be performed under conditions known in the art, for example when -Y is azide and -Y” is cyclooctyne the conjugation occurs in any solvent wherein both components show adequate solubility, although it is known that aqueous solutions show more favorable reaction rates.
  • an aqueous buffer typically an aqueous buffer at a pH of 2 to7 when -Y and -Y” are azide/cyclooctyne, or at a pH of 6 to 9 when -Y and -Y” are an activated ester and an amine
  • the -Y and -Y” groups react to form an insoluble hydrogel matrix comprising crosslinks of formula (PL-4').
  • a conjugate comprising a hydrogel Z is produced by a method comprising the steps of
  • -D is a drug moiety
  • -X- is absent when -D is a drug moiety connected through an amine, or -X- is -N(R 6 )CH2- when -D is a drug moiety connected through a phenol, alcohol, thiol, thiophenol, imidazole, or non-basic amine; wherein -R 6 is optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; so that -Y of formula (PL-5) reacts with -B’ of formula (PL-4);
  • step (c) providing the second prepolymer comprising a multi-arm polymer -P 1 wherein each arm is terminated by a reactive functional group -Y” that reacts with -Y of step (a) and wherein embodiments for -P 1 are described above;
  • a conjugate is obtained by a method comprising the step of reacting a hydrogel Z with the linker-drug of formula (PL-5), wherein -B’ on the hydrogel Z reacts with -Y of formula (PL-5). Only in the context of formulas (PL-4), (PL-4') and (PL-5) the terms used have the following meaning:
  • alkyl refers to linear, branched, or cyclic saturated hydrocarbon groups of 1 to 20, 1 to 12, 1 to 8, 1 to 6, or 1 to 4 carbon atoms.
  • an alkyl is linear or branched.
  • linear or branched alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t- butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n- octyl, n-nonyl, and n-decyl.
  • an alkyl is cyclic.
  • cyclic alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentadienyl, and cyclohexyl.
  • alkoxy refers to alkyl groups bonded to oxygen, including methoxy, ethoxy, isopropoxy, cyclopropoxy, and cyclobutoxy.
  • alkenyl refers to non-aromatic unsaturated hydrocarbons with carbon-carbon double bonds and 2 to 20, 2 to 12, 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
  • alkynyl refers to non-aromatic unsaturated hydrocarbons with carbon-carbon triple bonds and 2 to 20, 2 to 12, 2 to 8, 2 to 6, or 2 to 4 carbon atoms.
  • aryl refers to aromatic hydrocarbon groups of 6 to 18 carbons, preferably 6 to 10 carbons, including groups such as phenyl, naphthyl, and anthracenyl.
  • heteroaryl refers to aromatic rings comprising 3 to 15 carbons comprising at least one N, O or S atom, preferably 3 to 7 carbons comprising at least one N, O or S atom, including groups such as pyrrolyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, quinolyl, indolyl, and indenyl.
  • alkenyl, alkynyl, aryl or heteroaryl moieties may be coupled to the remainder of the molecule through an alkyl linkage.
  • the substituent will be referred to as alkenylalkyl, alkynylalkyl, arylalkyl or heteroarylalkyl, indicating that an alkylene moiety is between the alkenyl, alkynyl, aryl or heteroaryl moiety and the molecule to which the alkenyl, alkynyl, aryl or heteroaryl is coupled.
  • halogen refers to bromo, fluoro, chloro and iodo.
  • heterocyclic ring or “heterocyclyl” refers to a 3- to 15-membered aromatic or nonaromatic ring comprising at least one N, O, or S atom. Examples include piperidinyl, piperazinyl, tetrahydropyranyl, pyrrolidine, and tetrahydrofuranyl, as well as the exemplary groups provided for the term "heteroaryl” above.
  • a heterocyclic ring or heterocyclyl is nonaromatic.
  • a heterocyclic ring or heterocyclyl is aromatic.
  • substituents include alkyl, alkenyl, alkynyl, halogen, -CN, -OR aa ,
  • Z is a hyaluronic acid-based hydrogel as disclosed in WO2018/175788A1. In certain embodiments Z is a hyaluronic acid-based hydrogel as disclosed in W02020/064847A1.
  • Z is a water-soluble polymeric moiety.
  • Z comprises a polymer selected from the group consisting of linear, branched, dendritic, multi-arm or circular polymers or combination thereof. In certain embodiments Z comprises a linear polymer. In certain embodiments Z is a branched PEG-based polymer. In certain embodiments Z is a branched PEG-based polymer having one, two, three, four, five or six branching points. In certain embodiments Z is a branched PEG-based polymer having one, two or three branching points. In certain embodiments Z is a branched PEG-based polymer having one branching point. In certain embodiments Z is a branched PEG-based polymer having two branching points. In certain embodiments Z is a branched PEG-based polymer having two branching points.
  • Z is a branched PEG-based polymer having three branching points. In certain embodiments Z is a branched PEG-based polymer having four branching points. In certain embodiments a branching point is selected from the group consisting of -N ⁇ , -CH ⁇ and >C ⁇ . In certain embodiments Z comprises a dendritic polymer. In certain embodiments Z comprises a multiarm polymer, such as a polymer comprising 3, 4, 5, 6, 7, or 8 arms. In certain embodiments Z comprises a multi-arm polymer comprising 3 arms. In certain embodiments Z comprises a multi-arm polymer comprising 4 arms. In certain embodiments Z comprises a multi-arm polymer comprising 5 arms.
  • Z comprises a multi-arm polymer comprising 6 arms. In certain embodiments Z comprises a multi-arm polymer comprising 7 arms. In certain embodiments Z comprises a multi-arm polymer comprising 8 arms. In certain embodiments Z comprises a circular polymer. In certain embodiments Z comprises a polymer comprising any combination of a polymer selected from the group consisting of linear, branched, dendritic, multi-arm or circular polymers.
  • Z is a water-soluble polymeric moiety
  • such polymeric moiety may have a molecular weight ranging from and including 1 kDa to 1000 kDa.
  • Z has a molecular weight ranging from and including 5 kDa to 1000 kDa.
  • Z has a molecular weight ranging from and including 6 kDa to 500 kDa.
  • Z has a molecular weight ranging from and including 7 kDa to 250 kDa.
  • Z has a molecular weight ranging from and including 10 kDa to 150 kDa.
  • Z has a molecular weight ranging from and including 12 kDa to 100 kDa.
  • Z has a molecular weight ranging from and including 15 kDa to 80 kDa. In certain embodiments Z has a molecular weight ranging from and including 10 kDa to 80 kDa. In certain embodiments Z has a molecular weight of about 80 kDa. In certain embodiments Z has a molecular weight of about 70 kDa. In certain embodiments Z has a molecular weight of about 60 kDa. In certain embodiments Z has a molecular weight of about 50 kDa. In certain embodiments Z has a molecular weight of about 40 kDa. In certain embodiments Z has a molecular weight of about 30 kDa. In certain embodiments Z has a molecular weight of about 20 kDa. In certain embodiments Z has a molecular weight of about 10 kDa. In certain embodiments Z has a molecular weight of about 5 kDa.
  • Z is a water-soluble polymeric moiety comprising a polymer selected from the group consisting of 2-methacryloyl-oxyethyl phosphoyl cholins, poly(acrylic acids), poly(acrylates), poly(acrylamides), poly(alkyloxy) polymers, poly(amides), poly(amidoamines), poly(amino acids), poly( anhydrides), poly(aspartamides), poly(butyric acids), poly(glycolic acids), polybutylene terephthalates, poly(caprolactones), poly(carbonates), poly(cyanoacrylates), poly(dimethylacrylamides), poly(esters), poly(ethylenes), poly(ethyleneglycols), poly(ethylene oxides), poly(ethyl phosphates), poly(ethyloxazolines), poly(glycolic acids), poly(hydroxyethyl acrylates), poly(hydroxyethyl-oxazolines), poly(hydroxymethacrylates), poly(hydroxypropyl
  • Z is a water-soluble polymeric moiety comprising a protein, such as a protein selected from the group consisting of carboxyl-terminal peptide of the chorionic gonadotropin as described in US 2012/0035101 Al; albumin; XTEN sequences as described in WO 2011123813 A2; proline/alanine random coil sequences as described in WO 2011/144756 Al; proline/alanine/serine random coil sequences as described in WO 2008/155134 Al and WO 2013/024049 Al; and Fc- fusion proteins.
  • a protein such as a protein selected from the group consisting of carboxyl-terminal peptide of the chorionic gonadotropin as described in US 2012/0035101 Al; albumin; XTEN sequences as described in WO 2011123813 A2; proline/alanine random coil sequences as described in WO 2011/144756 Al; proline/alanine/serine random coil sequences as described in WO 2008/155
  • Z comprises a random coil protein moiety of which at least 80%, in certain embodiments at least 85%, in certain embodiments at least 90%, in certain embodiments at least 95%, in certain embodiments at least 98% and in certain embodiments at least 99% of the total number of amino acids forming said random coil protein moiety are selected from alanine and proline. In certain embodiments at least 10%, but less than 75%, in certain embodiments less than 65% of the total number of amino acid residues of such random coil protein moiety are proline residues. In certain embodiments such random coil protein moiety is as described in WO 2011/144756 Al.
  • Z comprises at least one moiety selected from the group consisting of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID N0:9, SEQ ID NO: 10, SEQ ID N0:11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO:51 and SEQ ID NO:61 as disclosed in WO2011/144756 which are hereby incorporated by reference.
  • a moiety comprising such random coil protein comprising alanine and proline will be referred to as “PA” or “PA moiety”. Accordingly, in certain embodiments Z comprises a PA moiety.
  • Z comprises a random coil protein moiety of which at least 80%, in certain embodiments at least 85%, in certain embodiments at least 90%, in certain embodiments at least 95%, in certain embodiments at least 98% and in certain embodiments at least 99% of the total number of amino acids forming said random coil protein moiety are selected from alanine, serine and proline. In certain embodiments at least 4%, but less than 40% of the total number of amino acid residues of such random coil protein moiety are proline residues. In certain embodiments such random coil protein moiety is as described in WO 2008/155134 Al.
  • Z comprises at least one moiety selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO: 10, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:52, SEQ ID NO:54 and SEQ ID NO:56 as disclosed in WO 2008/155134 Al, which are hereby incorporated by reference.
  • a moiety comprising such random coil protein moiety comprising alanine, serine and proline will be referred to as “PAS” or “PAS moiety”. Accordingly, in certain aspects
  • Z comprises a random coil protein moiety of which at least 80%, in certain embodiments at least 85%, in certain embodiments at least 90%, in certain embodiments at least 95%, in certain embodiments at least 98% and in certain embodiments 99% of the total number of amino acids forming said random coil protein moiety are selected from alanine, glycine, serine, threonine, glutamate and proline. In certain embodiments such random coil protein moiety is as described in WO 2010/091122 Al.
  • Z comprises at least one moiety selected from the group consisting of SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184; SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:196, SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID N0:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207, SEQ ID NO:208, SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:
  • a moiety comprising such random coil protein moiety comprising alanine, glycine, serine, threonine, glutamate and proline will be referred to as “XTEN” or “XTEN moiety” in line with its designation in WO 2010/091122 Al. Accordingly, in certain embodiments Z comprises an XTEN moiety.
  • Z comprises at least 60, such as at least 90 or at least 120, elastin-like peptide structural units selected from any one of SEQ ID NO:l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:l l, SEQ ID NO:12 and SEQ ID NO:13 of W02021/030196.
  • Z comprises the protein of SEQ ID NO:34 of W02021/030196.
  • Z comprises the protein of SEQ ID NO:35 of W02021/030196.
  • Z comprises a hyaluronic acid-based polymer.
  • Z comprises a polymeric moiety as disclosed in WO 2013/024047 Al. In certain embodiments Z comprises a polymeric moiety as disclosed in WO 2013/024048 Al.
  • Z comprises a multi-arm PEG-based polymer. In certain embodiments Z comprises a multi-arm PEG-based polymer having at least 2 PEG-based arms, such as 2, 3, 4, 5, 6, 7 or 8 PEG-based arms.
  • Z comprises a branched moiety of formula (Z-i)
  • -BP' ⁇ , -BP 2 ⁇ , -BP 3 ⁇ are independently of each other selected from the group consisting of -N ⁇ and -C(R 8 ) ⁇ ;
  • R 8 is selected from the group consisting of H, Ci-6 alkyl, C2-6 alkenyl and C2-6 alkynyl;
  • -P 1 , -P 2 , -P 3 , -P 4 are independently of each other a PEG-based chain comprising at least 40% PEG and having a molecular weight ranging from 2 to 45 kDa;
  • -C 1 -, -C 2 - are independently of each other selected from the group consisting of Ci-50 alkyl
  • C2-50 alkenyl, and C2-50 alkynyl wherein C 1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally substituted with one or more R 9 , which are the same or different and wherein C 1-50 alkyl, C2-50 alkenyl, and C2-50 alkynyl are optionally interrupted by one or more groups selected from the group consisting of -T-, -C(O)0-, -0-, -C(O)-, -C(O)N(R 10 )-, -S(O) 2 N(R 10 )-, -S(O)N(R 10 )-, -S(O) 2 -, -SCO)-, -N(R 10 )S(O) 2 N(R 10a )-, -S-,
  • BP 1 of formula (Z-i) is -N ⁇ .
  • BP 2 and BP 2 of formula (Z-i) are both -CH ⁇ . It is advantageous if the first branching point BP 1 and the attachment site of Z to -L 1 - are separated by no more than a certain number of atoms. Accordingly, in certain embodiments the critical distance is less than 60 atoms, such as less than 50 atoms, such as less than 40 atoms, such as less than 30 atoms, such as less than 20 atoms or less than 10 atoms.
  • critical distance refers to the shortest distance measured as the number of atoms between the first branching point BP 1 and attachment site of Z to -L 1 -.
  • P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from about 5 to about 40 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from about 8 to about 25 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from about 9 to about 22 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from about 9 to about 15 kDa.
  • P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from 10 to 12 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight of about 10 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from 15 to 22 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight ranging from 18 to 21 kDa. In certain embodiments P 1 , P 2 , P 3 and P 4 have each independently of the other a molecular weight of about 20 kDa.
  • C 1 and C 2 of formula (Z-i) are of formula (Z-ia) wherein the dashed line marked with the asterisk indicates attachment to BP 1 ; the unmarked dashed line indicates attachment to BP 2 or BP 3 , respectively; ql is 1, 2, 3, 4, 5, 6, 7 or 8; q2 is 1, 2, 3, 4, or 5; q3 is 1, 2, 3, 4, 5, 6, 7 or 8; q4 is 1, 2 or 3.
  • ql of formula (Z-ia) is 4, 5, 6, 7, or 8. In certain embodiments ql of formula (Z-ia) is 5, 6 or 7. In certain embodiments ql of formula (Z-ia) is 6. In certain embodiments q2 of formula (Z-ia) is 1, 2 or 3. In certain embodiments q3 of formula (Z-ia) is 2, 3, 4 or 5. In certain embodiments q3 is 2, 3 or 4. In certain embodiments q3 of formula (Z-ia) is 3. In certain embodiments q4 of formula (Z-ia) is 1.
  • P 1 , P 2 , P 3 and P 4 of formula (Z-i) are independently of each other of formula (Z-ib) wherein the dashed line indicates attachment the remainder of R 1 , i.e. to BP 2 or BP 3 , respectively; m is 0 or 1 ; p is an integer ranging from 45 to 1000; and q is selected from the group consisting of 1, 2, 3, 4, 5, and 6.
  • p of formula (Z-ib) ranges from 115 to 900. In certain embodiments p of formula (Z-ib) ranges from 180 to 580. In certain embodiments p of formula (Z-ib) ranges from 200 to 340. In certain embodiments p of formula (Z-ib) ranges from 220 to 270. In certain embodiments p of formula (Z-ib) ranges from 220 to 240. In certain embodiments p of formula (Z-ib) is about 225. In certain embodiments p of formula (Z-ib) ranges from 340 to 500. In certain embodiments p of formula (Z-ib) ranges from 410 to 475.
  • p of formula (Z-ib) is about 450.
  • Z comprises a moiety of formula (Z-ic): wherein pi, p2, p3 and p4 are independently an integer ranging from 45 to 1000.
  • pi, p2, p3 and p4 are independently an integer ranging from 115 to 900.
  • pi, p2, p3 and p4 are independently an integer ranging from 180 to 580.
  • pi, p2, p3 and p4 are independently an integer ranging from 200 to 340.
  • pi, p2, p3 and p4 are independently an integer ranging from 220 to 270.
  • pi, p2, p3 and p4 are independently an integer ranging from 220 to 240. In certain embodiments pi, p2, p3 and p4 are independently an integer ranging from 210 to 240. In certain embodiments pi, p2, p3 and p4 are independently about 225. In certain embodiments pi, p2, p3 and p4 are independently an integer ranging from 340 to 500. In certain embodiments pi, p2, p3 and p4 are independently an integer ranging from 410 to 475. In certain embodiments pi, p2, p3 and p4 are independently an integer ranging from 420 to 480. In certain embodiments pi, p2, p3 and p4 are independently about 450.
  • the growth hormone conjugate is a conjugate of formula (C-i), as disclosed for example in WO05099768 A2
  • -D is a hGH moiety connected to the rest of the molecule through the nitrogen of an amine functional group of -D; and pi, p2, p3 and p4 are independently an integer ranging from 400 to 500.
  • -D of formula (C-i) is a hGH moiety of SEQ ID NO:l. In certain embodiments -D of formula (C-i) is connected to the rest of the molecule through a nitrogen of an amine functional group provided by a lysine side chain of -D.
  • pi, p2, p3 and p4 of formula (C-i) are independently an integer ranging from 420 to 480. In certain embodiments pi, p2, p3 and p4 of formula (C-i) are independently an integer ranging from 420 to 470. In certain embodiments pi , p2, p3 and p4 of formula (C-i) are independently an integer ranging from 440 to 460. In certain embodiments pi, p2, p3 and p4 of formula (C-i) are about 450.
  • the growth hormone conjugate is a conjugate of formula (C-ii), as disclosed for example in W02016/079114A1
  • -D is a hGH moiety connected to the rest of the molecule through the nitrogen of an amine functional group of -D; and pi, p2, p3 and p4 are independently an integer ranging from 200 to 250.
  • -D of formula (C-ii) is a hGH moiety of SEQ ID NO:l. In certain embodiments -D of formula (C-ii) is connected to the rest of the molecule through a nitrogen of an amine functional group provided by a lysine side chain of -D.
  • pi, p2, p3 and p4 of formula (C-ii) are independently an integer ranging from 210 to 240. In certain embodiments pi, p2, p3 and p4 of formula (C-ii) are independently an integer ranging from 220 to 240. In certain embodiments pi, p2, p3 and p4 of formula (C-ii) are about 225.
  • the long-acting GH is of formula (C-ii) with -D being of SEQ ID NO:l, -D being connected to the rest of the molecule through a nitrogen of an amine functional group provided by a lysine side chain of -D and pi, p2, p3 and p4 independently being an integer ranging from 220 to 240, the long-acting GH is lonapegsomatropin, which is marketed in the US as Skytrofa ® .
  • the long-acting growth hormone is selected from the group consisting of Somatrogon, Albutropin, ARX201, ALTU-238, PHA-794428, hGH-OctoDex, Norditropin, Nutropin Depot, LB03002, Somatropin Biopartners, Efpegsomatropin, Somapacitan, Jintrolong, Eftansomatropin and TV- 1106.
  • the long-acting growth hormone is selected from the group consisting of Somatrogen, Albutropin, Norditropin, Nutropin Depot, Somatropin Biopartners, Efpegsomatropin, Somapacitan, Eftansomatropin and Jintrolong.
  • the long-acting growth hormone is Somatrogon. In certain embodiments the long-acting growth hormone is Albutropin. In certain embodiments the long-acting growth hormone is ARX201. In certain embodiments the long-acting growth hormone is ALTU-238. In certain embodiments the long-acting growth hormone is PHA-794428. In certain embodiments the long-acting growth hormone is hGH-OctoDex. In certain embodiments the long-acting growth hormone is Norditropin. In certain embodiments the long-acting growth hormone is Nutropin Depot. In certain embodiments the long-acting growth hormone is LB03002. In certain embodiments the long-acting growth hormone is Somatropin Biopartners.
  • the long-acting growth hormone is Efpegsomatropin. In certain embodiments the long-acting growth hormone is Somapacitan. Somapacitan is marketed as Sogroya ® . In certain embodiments the long-acting growth hormone is TV-1106. In certain embodiments the long-acting growth hormone is Jintrolong. In certain embodiments the long-acting growth hormone is Eftansomatropin.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising at least one long-acting growth hormone and at least one excipient for use in the treatment of an inflammation-induced disease, wherein the at least one long-acting growth hormone and the treatment are as described elsewhere herein.
  • such pharmaceutical composition has a pH ranging from and including pH 3 to pH 8.
  • such pharmaceutical composition is a suspension formulation.
  • such pharmaceutical composition is a liquid formulation.
  • such pharmaceutical composition is a dry formulation.
  • Such liquid, suspension or dry pharmaceutical composition comprises at least one excipient.
  • Excipients used in parenteral formulations may be categorized as, for example, buffering agents, isotonicity modifiers, preservatives, stabilizers, anti-adsorption agents, oxidation protection agents, viscosifiers/viscosity enhancing agents, or other auxiliary agents. However, in some cases, one excipient may have dual or triple functions.
  • the at least one excipient of the pharmaceutical composition of the present invention is selected from the group consisting of (i) Buffering agents: physiologically tolerated buffers to maintain pH in a desired range, such as sodium phosphate, bicarbonate, succinate, histidine, citrate and acetate, sulphate, nitrate, chloride, pyruvate; antacids such as Mg(OH)2 or ZnCCb may be also used;
  • Isotonicity modifiers to minimize pain that can result from cell damage due to osmotic pressure differences at the injection depot; glycerin and sodium chloride are examples; effective concentrations can be determined by osmometry using an assumed osmolality of 285-315 mOsmol/kg for serum;
  • Preservatives and/or antimicrobials multidose parenteral formulations require the addition of preservatives at a sufficient concentration to minimize risk of patients becoming infected upon injection and corresponding regulatory requirements have been established; typical preservatives include m-cresol, phenol, methylparaben, ethylparaben, propylparaben, butylparaben, chlorobutanol, benzyl alcohol, phenylmercuric nitrate, thimerosol, sorbic acid, potassium sorbate, benzoic acid, chlorocresol, and benzalkonium chloride;
  • Stabilizers Stabilisation is achieved by strengthening of the protein-stabilising forces, by destabilisation of the denatured state, or by direct binding of excipients to the protein; stabilizers may be amino acids such as alanine, arginine, aspartic acid, glycine, histidine, lysine, proline, sugars such as glucose, sucrose, trehalose, polyols such as glycerol, mannitol, sorbitol, salts such as potassium phosphate, sodium sulphate, chelating agents such as EDTA, hexaphosphate, ligands such as divalent metal ions (zinc, calcium, etc.), other salts or organic molecules such as phenolic derivatives; in addition, oligomers or polymers such as cyclodextrins, dextran, dendrimers, PEG or PVP or protamine or HSA may be used;
  • Anti-adsorption agents Mainly ionic or non-ionic surfactants or other proteins or soluble polymers are used to coat or adsorb competitively to the inner surface of the formulation's container; e.g., poloxamer (Pluronic F-68), PEG dodecyl ether (Brij 35), polysorbate 20 and 80, dextran, polyethylene glycol, PEG-polyhistidine, BSA and HSA and gelatins; chosen concentration and type of excipient depends on the effect to be avoided but typically a monolayer of surfactant is formed at the interface just above the CMC value;
  • Oxidation protection agents antioxidants such as ascorbic acid, ectoine, methionine, glutathione, monothioglycerol, morin, polyethylenimine (PEI), propyl gallate, and vitamin E; chelating agents such as citric acid, EDTA, hexaphosphate, and thioglycolic acid may also be used;
  • Viscosifiers or viscosity enhancers retard settling of the particles in the vial and syringe and are used in order to facilitate mixing and resuspension of the particles and to make the suspension easier to inject (i.e., low force on the syringe plunger); suitable viscosifiers or viscosity enhancers are, for example, carbomer viscosifiers like Carbopol 940, Carbopol Ultrez 10, cellulose derivatives like hydroxypropylmethylcellulose (hypromellose, HPMC) or diethylaminoethyl cellulose (DEAE or DEAE-C), colloidal magnesium silicate (Veegum) or sodium silicate, hydroxyapatite gel, tricalcium phosphate gel, xanthans, carrageenans like Satia gum UTC 30, aliphatic poly(hydroxy acids), such as poly(D,L- or L-lactic acid) (PLA) and poly(glycolic acid) (PGA) and their
  • Pluronic® polyetherester copolymer, such as a polyethylene glycol terephthalate/polybutylene terephthalate copolymer, sucrose acetate isobutyrate (SAIB), dextran or derivatives thereof, combinations of dextrans and PEG, polydimethylsiloxane, collagen, chitosan, polyvinyl alcohol (PVA) and derivatives, polyalkylimides, poly (acrylamide-co- diallyldimethyl ammonium (DADMA)), polyvinylpyrrolidone (PVP), glycosaminoglycans (GAGs) such as dermatan sulfate, chondroitin sulfate, keratan sulfate, heparin, heparan sulfate, hyaluronan, ABA triblock or AB block copolymers composed of hydrophobic A-blocks, such as polylactide (PLA) or poly(lactide-co
  • Spreading or diffusing agent modifies the permeability of connective tissue through the hydrolysis of components of the extracellular matrix in the interstitial space such as but not limited to hyaluronic acid, a polysaccharide found in the intercellular space of connective tissue; a spreading agent such as but not limited to hyaluronidase temporarily decreases the viscosity of the extracellular matrix and promotes diffusion of injected drugs; and
  • auxiliary agents such as wetting agents, viscosity modifiers, antibiotics, hyaluronidase; acids and bases such as hydrochloric acid and sodium hydroxide are auxiliary agents necessary for pH adjustment during manufacture.
  • the present invention relates to a long-acting growth hormone for use in the treatment of an inflammation-induced disease, wherein administration of the long-acting growth hormone inhibits recruitment of inflammatory monocytes to the site of inflammation.
  • the inflammation-induced disease is NAFLD, such as NASH.
  • the site of inflammation is the liver, if the inflammation-induced disease is NAFLD, in particular NASH.
  • administration of the long-acting growth hormone leads to an increase in HLA-G in the liver, if the inflammation-induced disease is NAFLD, in particular NASH.
  • the long-acting growth hormone for use in the treatment of an inflammation-induced disease results in an increase in IGF-1 levels.
  • the long-acting growth hormone for use in the treatment of an inflammation- induced disease leads to a change in one or more markers of hepatic inflammation selected from the group consisting of cytokines, chemokines and other transcriptional and histological markers.
  • the long-acting growth hormone for use in the treatment of an inflammation-induced disease leads to an improvement of transcriptional or histological markers of fibrosis.
  • the long-acting growth hormone for use in the treatment of an inflammation- induced disease such as NAFLD and in particular of NASH, leads to a reduction in steatosis.
  • the long-acting growth hormone for use in the treatment of an inflammation- induced disease of the liver such as NAFLD and in particular of NASH, leads to a regeneration of the liver.
  • the long-acting growth hormone and, administration frequencies are as described elsewhere herein.
  • Compound 1 may be synthesized as described in W02016/079114A1 for compound 2 (example 2) and corresponds to lonapegsomatropin.
  • Example 2
  • the plasma pharmacokinetics profile was determined in a pre-study after a single injection (14.4 mg/kg) of compound 1 to C57BL/6JRJ mice and blood samples were collected over 96 hours.
  • the plasma level of compound 1 was determined using a sandwich ELISA. All concentrations of compound 1 are in protein (hGH) equivalents.
  • mice C57BL/6JRj mice (Janvier (France, 5 weeks old)), were fed a non-alcoholic steatohepatitis (NASH) inducing diet consisting with 40% fat, 22% fructose and 2% cholesterol (D09100310, SSNIFF, Germany) for a total of 32 weeks.
  • NASH non-alcoholic steatohepatitis
  • HE picrosirius red and
  • RNAseq RNA Sequencing
  • Paraffin embedded sections were de-paraffinated in xylene and rehydrated in series of graded ethanol before HE stain (HE; Dako), CD68 (clone EDI, Abeam, Cat. Ab31630) and CDl lb (AbCam, Cat. 133357).
  • IHC was performed using standard procedures. IHC-positive staining was quantified by image analysis using the VIS software (Visiopharm, Denmark). The number of hepatocytes with lipid droplets and inflammatory foci were determined by deep learning apps developed by Gubra using the VIS software.
  • ALT Plasma alanine transaminase
  • AST aspartate transaminase
  • TC total cholesterol
  • RNA was isolated using the NucleoSpin® kit (MACHEREY-NAGEL) using a total of 10 ng-1 pg purified RNA from each bulk liver sample.
  • Aa cDNA library was generated using the NEBNext® UltraTM II Directional RNA Library Prep Kit for Illumina (New England Biolabs) and then sequenced on a NextSeq 500 using NextSeq 500/550 High Output Kit V2 (Illumina).
  • the sequencing data was aligned to the mouse genome (Ensembl database) using the Spliced Transcripts Alignment to a Reference (STAR) software.
  • the quality of the data was evaluated using the standard RNA-sequencing quality control parameters, the inter- and intra-group variability was evaluated using principal component analysis and hierarchical clustering and the differentially expressed genes were identified using the R-package DESeq2.
  • the inflammatory state of the liver was examined via histological analysis and gene expression analysis.
  • CD1 lb inflammation marker cluster of differentiation l ib
  • CD 14 Monocyte chemoattractant protein- 1
  • CCR1 C-C Motif Chemokine Receptor 1
  • CCR2 C-C Motif Chemokine Receptor 2
  • a-SMA alpha-smooth muscle actin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une hormone de croissance (GH) à action prolongée destinée à être utilisée dans le traitement d'une maladie induite par une inflammation.
EP22713687.6A 2021-04-01 2022-03-31 Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation Pending EP4314035A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21166699 2021-04-01
PCT/EP2022/058584 WO2022207798A1 (fr) 2021-04-01 2022-03-31 Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation

Publications (1)

Publication Number Publication Date
EP4314035A1 true EP4314035A1 (fr) 2024-02-07

Family

ID=75362497

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22713687.6A Pending EP4314035A1 (fr) 2021-04-01 2022-03-31 Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation

Country Status (10)

Country Link
EP (1) EP4314035A1 (fr)
JP (1) JP2024514095A (fr)
KR (1) KR20230164709A (fr)
CN (1) CN117396497A (fr)
AU (1) AU2022246997A1 (fr)
BR (1) BR112023018802A2 (fr)
CA (1) CA3212417A1 (fr)
IL (1) IL307192A (fr)
MX (1) MX2023011059A (fr)
WO (1) WO2022207798A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115845032A (zh) * 2022-10-28 2023-03-28 深圳科兴药业有限公司 生长激素fc融合蛋白注射液及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
WO2004089280A2 (fr) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Medicaments pegyles reversibles
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
BRPI0414539B8 (pt) 2003-09-19 2021-05-25 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
US8377917B2 (en) 2004-03-23 2013-02-19 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
JP2010503707A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド オリゴヌクレオチドの送達を目的としたヒンダードエステル系生体分解性リンカー
DK2369005T3 (da) 2007-06-21 2013-06-24 Univ Muenchen Tech Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
EP2175878A4 (fr) 2007-07-11 2014-12-03 Belrose Pharma Inc Système d'administration de médicament polymérique contenant un groupement aromatique multi-substitué
RU2010136023A (ru) 2008-02-01 2012-03-10 Асцендис Фарма Ас (Dk) Пролекарство, содержащее саморасщепляемый линкер
EP2288261A4 (fr) 2008-05-23 2013-09-25 Enzon Pharmaceuticals Inc Systèmes polymères contenant un lieur disulfure intracellulaire libérable pour la délivrance d oligonucléotides
CN102348715B (zh) 2009-02-03 2017-12-08 阿穆尼克斯运营公司 延伸重组多肽和包含该延伸重组多肽的组合物
HUE052816T2 (hu) 2009-07-31 2021-05-28 Ascendis Pharma As Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek
EP2519228A4 (fr) 2009-12-31 2013-06-19 Enzon Pharmaceuticals Inc Conjugués polymères de composés contenant un groupement amine aromatique comprenant un lieur d'urée libérable
EP3372617B1 (fr) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
WO2011140392A1 (fr) 2010-05-05 2011-11-10 Prolynx Llc Supports solides pour la libération contrôlée de médicaments
JP5977229B2 (ja) 2010-05-05 2016-08-24 プロリンクス リミテッド ライアビリティ カンパニー 巨大分子共役体からの徐放
EP2571510B1 (fr) 2010-05-21 2018-08-08 XL-protein GmbH Polypeptides de bobine aléatoires en proline/alanine biosynthétique
EP2741778A1 (fr) 2011-08-12 2014-06-18 Ascendis Pharma A/S Promédicaments liés à des excipients polymériques hyperbranchés
EP2741782B1 (fr) 2011-08-12 2020-05-06 Ascendis Pharma A/S Prodrogues liés à un support protéinique
CA2843875C (fr) 2011-08-12 2020-01-07 Ascendis Pharma A/S Promedicaments lies a des excipients hydrosolubles de forte charge
JP6158185B2 (ja) 2011-09-07 2017-07-05 プロリンクス エルエルシー 生分解性架橋を有するヒドロゲル
WO2013036857A1 (fr) 2011-09-07 2013-03-14 Prolynx Llc Coupleurs au sulfone
JP6271566B2 (ja) 2012-10-11 2018-01-31 アセンディス ファーマ エー／エス ヒドロゲルプロドラッグ
JP2015536314A (ja) 2012-10-17 2015-12-21 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン送達のための脂肪酸アシル化アミノ酸
EP3193941B1 (fr) 2014-08-06 2024-05-22 Ascendis Pharma A/S Promédicaments comprenant un liant de type aminoalkylglycine
IL307773A (en) 2014-11-18 2023-12-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric human growth hormone drug matrices
KR20240150530A (ko) 2017-03-22 2024-10-15 아센디스 파마 에이에스 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
CN112770781A (zh) 2018-09-26 2021-05-07 阿森迪斯药物股份有限公司 新的水凝胶缀合物
EP3856257A1 (fr) 2018-09-26 2021-08-04 Ascendis Pharma A/S Hydrogels dégradables d'acide hyaluronique
CN114286693A (zh) 2019-04-05 2022-04-05 普罗林科斯有限责任公司 改良偶联接头
US20220289812A1 (en) 2019-08-09 2022-09-15 Phasebio Pharmaceuticals, Inc. Elp fusion proteins comprising parathyroid hormone for controlled and sustained release

Also Published As

Publication number Publication date
MX2023011059A (es) 2023-09-29
CA3212417A1 (fr) 2022-10-06
BR112023018802A2 (pt) 2023-10-31
JP2024514095A (ja) 2024-03-28
CN117396497A (zh) 2024-01-12
IL307192A (en) 2023-11-01
AU2022246997A1 (en) 2023-09-28
AU2022246997A9 (en) 2024-01-25
KR20230164709A (ko) 2023-12-04
WO2022207798A1 (fr) 2022-10-06

Similar Documents

Publication Publication Date Title
US20230302091A1 (en) Combination Therapy with Controlled-Release CNP Agonists
US20190255183A1 (en) Cnp prodrugs
EP3773680A1 (fr) Conjugués d'il-2
AU2019270464B2 (en) Starting dose of PTH conjugates
WO2021144249A1 (fr) Traitement de l'hypoparathyroïdisme
EP4314035A1 (fr) Utilisation d'une hormone de croissance à action prolongée pour le traitement de maladies induites par une inflammation
CA3093083A1 (fr) Conjugues
WO2020254606A1 (fr) Conjugués de composés hétéroaromatiques contenant de l'azote
RU2806753C2 (ru) Способ лечения или контроля гипопаратиреоза с помощью конъюгата паратиреоидного гормона (ртн)
AU2021349316A9 (en) Improvement of physical and mental well-being of patients with hypoparathyroidism
AU2021349316A1 (en) Improvement of physical and mental well-being of patients with hypoparathyroidism
AU2022350937A1 (en) Long-acting pth compound treatments

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20231023

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20240213

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40106647

Country of ref document: HK